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ABSTRACT	
Whether	screening	the	metabolic	activity	of	immune	cells	facilitates	discovery	of	molecular	pathology	
remains	 unknown.	 Here	 we	 prospectively	 screened	 the	 extracellular	 acidification	 rate	 (ECAR)	 as	 a	
measure	of	glycolysis	and	the	oxygen	consumption	rate	(OCR)	as	a	measure	of	mitochondrial	respiration	
in	B	cells	from	patients	with	primary	antibody	deficiency	(PAD).	The	highest	OCR	values	were	detected	
in	three	study	participants	with	persistent	polyclonal	B	cell	 lymphocytosis	(PPBL).	Exome	sequencing	
identified	germline	mutations	in	SDHA,	which	encodes	succinate	dehydrogenase	subunit	A,	in	all	three	
patients	 with	 PPBL.	 SDHA	 gain-of-function	 led	 to	 accumulation	 of	 fumarate	 in	 PPBL	 B	 cells,	 which	
engaged	the	KEAP1–Nrf2	system	to	drive	the	transcription	of	genes	encoding	inflammatory	cytokines.	In	
a	single	patient	trial,	blocking	the	activity	of	the	cytokine	IL-6	in	vivo	prevented	systemic	inflammation	
and	ameliorated	clinical	disease.	Overall,	our	study	has	identified	pathological	mitochondrial	retrograde	
signaling	as	a	disease	modifier	in	PAD.	 	
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Primary	 immunodeficiency	 disorders	 (PIDs)	 are	 rare	 genetic	 syndromes	 arising	 from	 defects	 in	 the	
immune	 system1.	 The	 majority	 of	 PID	 patients	 display	 primary	 antibody	 deficiency	 (PAD)	 that	 can	
develop	due	 to	B	cell	 intrinsic	defects2.	The	causes	and	genetic	background	of	PADs	are	complex	and	
pathogenic	mutations	have	been	identified	only	in	a	minority	of	cases3,	4,	5.	PADs	present	with	a	spectrum	
of	clinical	problems,	ranging	 from	infections	 to	autoinflammation,	autoimmunity,	 lymphoproliferation	
and	enteropathy.	Non-infectious	complications	are	typically	unaffected	by	immunoglobulin	replacement	
therapy	 and	 contribute	 to	 excess	mortality6.	 The	 spectrum	 of	 clinical	 presentation	 is	 broad	 even	 in	
patients	 harboring	 the	 same	 pathogenic	 mutations,	 pointing	 to	 disease	 modifiers	 shaping	 clinical	
features6.	
Cellular	 metabolism	 governs	 immune	 cell	 function7,	 8,	 9.	 Specifically,	 various	 facets	 of	 glycolysis	 and	
glutaminolysis	impact	the	function	of	B	cells10,	11,	12,	13.	Glutaminolysis	can	contribute	to	ATP	production,	
and	glutamine-derived	α-ketoglutarate	(α-KG)	serves	as	an	anaplerotic	source	of	tricarboxylic	acid	(TCA)	
cycle	 metabolites14.	 Mitochondrial	 oxidative	 phosphorylation	 (OxPhos)	 produces	 most	 of	 the	 ATP	
required	 for	 anabolic	 processes	 in	 immune	 cells15.	 Non-bioenergetic	 features	 of	 mitochondria	 also	
regulate	immune	cell	function.	Production	of	mitochondrial	reactive	oxygen	species	(mROS)	has	been	
linked	to	the	activation	of	the	transcription	factor	NFAT	in	CD4+	T	cells	and	to	inhibition	of	the	B	cell	
antigen	 receptor	 (BCR)	 signaling	 in	 B	 cells16,	 17.	 In	 T	 cells,	 mitochondrial	 function	 and	 epigenetic	
remodeling	are	interlinked	via	pyruvate	oxidation	and	conversion	of	pyruvate-derived	citrate	to	acetyl-
CoA,	which	is	required	for	histone	acetylation18,	19.	Metabolites	of	the	TCA	cycle	can	also	directly	activate	
(a-KG),	or	inhibit	(fumarate,	succinate)	dioxygenases	involved	in	histone	and	DNA	demethylation,	thus	
modulating	 transcriptional	 activity.	 This	 process	 of	 mitochondrial	 metabolites	 impacting	 nuclear	
transcriptional	 processes	 is	 known	 as	 ‘mitochondrial	 retrograde	 signaling’20.	 Indeed,	 the	 a-
KG/fumarate+succinate	 ratio	 dictates	 epigenetic	 changes	 and	 transcriptional	 programs	 in	
macrophages21,	22.	 Protein	 succination,	 the	 fumarate-dependent,	 non-enzymatic	addition	of	 a	 succinyl	
group	to	thiol	groups	in	proteins,	provides	another	emerging	link	between	mitochondrial	function	and	
transcriptional	activity	of	cells23.	
In	this	study	we	assessed	whether	B	cell	metabolic	screening	can	identify	PAD	patients	suffering	from	
disease	modifying	metabolic	dysregulation.	We	found	that	B	cell	OxPhos	served	as	a	functional	biomarker	
that	helped	decipher	a	pathogenic	immunometabolic	dysregulation	in	B	cells,	which	directed	a	successful	
clinical	intervention.	 	
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RESULTS	
Oxygen	consumption	rates	are	increased	in	PPBL	B	cells	
To	establish	normal	values	for	mitochondrial	respiration	and	glycolysis	in	B	cells,	we	measured	oxygen	
consumption	 rates	 (OCR)	 and	 extracellular	 acidification	 rates	 (ECAR),	 respectively,	 from	 15	 healthy	
individuals	and	14	patients	with	PAD	using	a	metabolic	flux	analyzer.	We	detected	higher	OCR	in	PAD	B	
cells	compared	to	healthy	controls	(HC),	while	ECAR	was	similar	in	both	groups	(Fig.	1a).	No	strong	age	
dependence	or	differences	between	sex	or	CMV	sero-positivity	in	OCR	or	ECAR	was	observed	in	either	
group	(Supplementary	Fig.	1a,b).	Basal	OCR	from	3	PAD	patients	(patients	1,	8	and	9),	all	diagnosed	with	
persistent	polyclonal	B	cell	lymphocytosis	(PPBL),	was	2.2-fold	higher	than	in	HC	(Supplementary	Table	
1a).	PPBL	is	a	rare	immune	dysregulation	characterized	by	expansion	of	IgD+CD27+	marginal	zone-like	
(MZ-like)	B	cells,	elevated	IgM,	and	low	IgG	in	the	serum24,	25.	Patient	1,	8	and	9,	the	only	PPBL	patients	
initially	included	in	this	study,	all	had	clinically	manifest	disease	(Supplementary	Table	1a,	b).	Patient	9	
had	 the	most	 severe	disease	 course,	 characterized	by	 systemic	 inflammation,	cutaneous	 small-vessel	
vasculitis	(leukocytoclastic	vasculitis),	and	periaortitis	(Fig.	1b).	About	80%	of	total	B	cells	from	patients	
1,	8	and	9	were	IgD+CD27+TACI+CD24+CD38–	cells,	reminiscent	of	murine	marginal	zone	B	cells	(hereafter	
marginal	zone	(MZ)-like	B	cells),	compared	to	approx.	20%	in	HC	(Fig.	1c	and	Supplementary	Fig.	1c).	
Thus,	for	downstream	experiments,	we	used	total	B	cells	from	PPBL	patients,	which	are	primarily	MZ-
like	B	cells	(hereafter	PPBL	B	cells).	Proliferation	of	PPBL	B	cells	was	similar	to	that	of	IgD+CD27–	naïve	B	
cells	 and	 IgD+CD27+	 MZ-like	 B	 cells	 from	 HC,	 following	 stimulation	 with	 CpG	 or	 IL-21+CD40L	
(Supplementary	Fig.	1d).	Further,	OCR	and	ECAR	of	HC	MZ-like	B	cells	was	similar	to	that	of	total	B	cells	
from	HC,	but	less	than	OCR	from	PPBL	B	cells	(Fig.	1d),	indicating	that	hyper-respiration	was	PPBL	B	cell-
intrinsic.	Both	OCR	and	ECAR	of	total	B	cells	from	all	3	PPBL	patients	remained	stable	~12	months	after	
baseline	measurements	(Fig.	1d).	The	high	OCR	in	B	cells	from	patient	9	was	not	affected	by	treatment	
with	the	rapamycin	synthetic	analogue	sirolimus	(Fig.	1e).	ECAR	was	similarly	increased	in	PPBL	B	cells	
and	HC	total	B	cells	treated	with	IL-21+CD40L	(Fig.	1f),	and	glucose	uptake	under	activating	conditions	
was	 also	 similar	 (Fig.	 1g),	 indicating	 glycolysis	 was	 not	 dysregulated	 in	 PPBL	 B	 cells.	 The	 relative	
distribution	of	CD27+CD45RO-	naïve,	CD27+CD45RO+	central	memory	(TCM),	and	CD27-CD45RO+	effector	
memory	(TEM)	CD4+	and	CD8+	T	cells	and	the	proliferation	of	total	CD4+	and	CD8+	T	cells	stimulated	with	
antibodies	against	CD3+CD28	were	similar	between	HC	and	PPBL	patients	(Supplementary	Fig.	1e,f).	
Additionally,	 production	 of	 IFN-g	 in	 CMV-specific	 T	 cells,	 basal	 respiration,	 glycolysis	 and	 the	
mitochondrial	membrane	potential	were	similar	between	the	two	groups	(Supplementary	Fig.	1g,h).	As	
such,	total	B	cells	from	3	PPBL	patients	had	increased	OCR	compared	to	HC	MZ-like	B	cells,	while	there	
was	no	evidence	for	altered	T	cell	function	or	metabolism.	
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Complex	II	is	hyper-functional	in	PPBL	B	cells	
Next,	we	analyzed	mitochondria	 in	PPBL	B	cells	by	electron	microscopy.	Mitochondria	cristae,	matrix	
morphology,	 number	 and	 area	 per	 cell,	 mitochondrial	 shape,	 as	 well	 as	 total	 cell	 area	 were	 similar	
between	PPBL	B	cells	and	HC	total	B	cells	(Supplementary	Fig.	2a).	The	protein	abundance	of	NDUFB8	
(complex	I),	succinate	dehydrogenase	(SDH)	B	(complex	II),	UQCRC2	(complex	III),	COX	II	(complex	IV)	
and	ATP5A	(complex	V)	were	also	similar	between	HC	and	PPBL	total	B	cells	(Supplementary	Fig.	2b).	
Using	blue	native	(BN)-PAGE	 immunoblot	analyses	on	mitochondria	enriched	 fractions,	expression	of	
complexes	I–IV,	formation	of	complex	I	containing	super-complexes	(I+III	and	I+III+IV)	and	assembly	of	
complex	III+IV	was	similar	between	EBV-immortalized	B	cell	lines	(hereafter	B-LCLs)	derived	from	HC	
MZ-like	 B	 cells	 and	 PPBL	 B	 cells	 (Supplementary	 Fig.	 2c).	 Mitochondrial	 membrane	 potential,	 as	
measured	using	MTR	and	MTDR,	was	moderately	increased	in	PPBL	B	cells	compared	to	HC	MZ-like	B	
cells	(Supplementary	Fig.	2d).	
The	enzymatic	activities	of	complexes	 I,	 IV	and	V	were	 identical,	while	 the	activity	of	complex	 II	was	
robustly	increased	in	all	3	PPBL	B-LCLSs	derived	from	each	patient	compared	to	HC	MZ-like	B-LCLs	(Fig.	
2a),	indicating	a	complex	II-intrinsic	gain-of-function	in	these	cells.	To	test	the	function	of		respiratory	
complexes	 I–IV	 in	 their	 normal	 structural	 context,	 their	 contribution	 to	 oxygen	 consumption	 was	
assessed	in	permeabilized	cells26.	A	selective	increase	in	complex	II	function,	which	was	not	altered	by	
the	complex	I	 inhibitor	rotenone,	was	observed	in	PPBL	B-LCLs	compared	to	HC	MZ-like	B-LCLs	(Fig.	
2b,c).	Immunoblot	analyses	of	the	complex	I	subunit	Grim19,	involved	in	electron	transfer,	and	SDHA,	
the	major	catalytic	subunit	of	complex	II,	did	not	detect	differences	in	protein	abundance	between	patient	
B-LCLs	 and	 HC	MZ-like	 B-LCLs	 (Fig.	 2d).	 These	 findings	 revealed	 a	 subtle,	 yet	 robust,	 difference	 in	
mitochondrial	function	that	was	linked	to	increased	SDH-complex	II	activity	in	PPBL	B-LCLs	compared	
to	HC	MZ-like	B-LCLs.	
	
Glutaminolysis	contributes	to	TCA	fueling	in	PPBL	B	cells	
To	gain	insight	into	the	metabolic	landscape	of	B	cells	from	PPBL	patients,	we	performed	metabolomic	
analyses	 on	 total	 PPBL	 B	 cells	 and	 sorted	 IgD+CD27+	 MZ-like	 B	 cells	 from	 HC.	 Several	 glycolytic	
intermediates	 such	 as	 dihydroxyacetone	 phosphate	 (DHAP),	 2-phosphoglycerate	 (2-PG)	 and	
phosphoenolpyruvate	(PEP)	were	 increased	in	PPBL	B	cells	compared	to	HC	MZ-like	B	cells,	whereas	
pyruvate	was	similarly	abundant	(Fig.	3a).	Moreover,	we	detected	an	almost	6-fold	increase	in	fumarate	
and	malate	in	PPBL	B	cells	compared	to	HC	MZ-like	B	cells	(Fig.	3a).	Other	TCA	cycle	metabolites	(citrate,	
aconitate	and	a-KG),	as	well	as	glutamate	were	also	more	abundant	in	PPBL	B	cells	than	in	HC	MZ-like	B	
cells	(Fig.	3a).	These	findings	suggested	increased	glutaminolysis	in	PPBL	B	cells	compared	to	HC	MZ-
like	B	cells.	As	observed	 in	primary	PPBL	B	cells,	accumulation	of	 fumarate	was	also	evident	in	PPBL	
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derived	B-LCLs	(Fig.	3b).	Of	note,	whereas	the	fumarate/succinate	ratio	was	increased	in	PPBL	B	cells,	
the	a-KG/fumarate+succinate	ratio	was	similar	between	HC	MZ-like	and	PPBL	B	cells	(Fig.	3c),	because	
a-KG	was	also	more	abundant	in	PPBL	B	cells.	Using	metabolic	tracing	studies,	abundant	m+5	(a-KG)	and	
m+4	(succinate,	fumarate,	malate	and	citrate)	isotopologues	of	TCA	cycle	metabolites	were	detected	in	
primary	PPBL	B	cells	cultured	with	13C-glutamine,	whilst	M+2	and	M+4	isotopologues	derived	from	13C-
glucose	were	less	abundant	(Fig.	3d),	indicating	that	glutaminolysis	contributed	to	anaplerotic	fueling	of	
the	 TCA	 cycle	 in	 PPBL	 B	 cells.	 These	 results	 revealed	 the	 accumulation	 of	 fumarate	 in	 PPBL	B	 cells	
compared	to	HC	MZ-like	B	cells,	and	indicated	that	glutamine	is	an	important	fuel	source	of	the	TCA	cycle	
in	PPBL	B	cells.	
	
PPBL	B	cells	have	an	inflammatory	transcriptional	profile	
We	then	investigated	the	transcriptional	profile	of	primary	PPBL	B	cells.	Of	the	13’107	gene	transcripts	
that	 were	 detected,	 mRNA	 abundance	 of	 1’878	 genes	 (14.33%)	 differed	 in	 a	 statistically	 significant	
manner	between	PPBL	B	cells	and	HC	MZ-like	B	cells,	as	indicated	by	unsupervised	hierarchical	clustering	
of	the	samples	(Fig.	4a).	Genes	typically	expressed	in	MZ-like	B	cells,	such	as	ITM2C,	JAM3	and	CD80	were	
also	 abundant	 in	 PPBL	 B	 cells27,	 28(Fig.	 4b),	 suggesting	 their	 close	 relationship.	 Metabolic	 genes,	
specifically	those	involved	in	the	TCA	cycle	(PC,	IDH),	glycolysis	(HK,	ALDOC)	and	glutamine	metabolism	
(DDAH2)	were	differentially	expressed	between	primary	PPBL	B	cells	and	HC	MZ-like	B	cells,	but	fold	
expression	differences	were	mostly	moderate	and	ranged	between	-2	and	2	 log2-fold	(Supplementary	
Fig.	3a).	Of	note,	the	transcripts	of	complex	II	genes	were	not	differentially	expressed	(Fig.	4c).	Genes	
encoding	other	respiratory	complexes	were	different	in	PPBL	B	cells	and	HC	MZ-like	B	cells,	but	the	fold	
expression	differences	typically	ranged	between	-1	and	1	log2-fold	(Supplementary	Fig.	3b).	On	the	other	
hand,	 transcripts	 annotated	 to	 the	 inflammatory	 response	 and	 the	 IL-6–Jak–STAT3	 pathway	 were	
enriched	in	PPBL	B	cells	relative	to	HC	MZ-like	B	cells	(Fig.	4d).	Transcripts	for	CXCL8,	IL1B,	CCL5,	IL6	
and	TNF,	all	induced	during	inflammation,	were	consistently	more	abundant	in	PPBL	B	cells	than	HC	MZ-
like	 B	 cells	 (Fig.	 4e).	 Moreover,	 the	 abundance	 of	 IL-6	 and	 IL-8	 protein	 was	 also	 increased	 in	 the	
supernatant	of	PPBL	B-LCLs	compared	to	HC	MZ-like	B-LCLs	(Fig.	4f).	In	2	separate	measurements,	the	
concentration	of	IL-6	was	moderately	increased	in	the	serum	of	patient	8	relative	to	mean	clinical	values	
in	HC	(Fig.	4g).	Together,	these	findings	demonstrated	that	PPBL	B	cells	shared	similar	transcriptomic	
profiles	as	MZ-like	B	cells,	however,	these	cells	also	displayed	increased	inflammatory	gene	expression.	
	
SDH	drives	an	inflammatory	phenotype	in	PPBL	B	cells	
To	assess	whether	hyperactive	SDH	and	increased	cytokine	production	in	PPBL	B	cells	were	linked,	we	
probed	the	effect	of	the	SDH	inhibitor	3-nitropropionic	acid	(3-NPA)	on	mitochondrial	respiration	and	
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IL-6	 production.	 Basal	 OCR,	 complex	 II	 respiration	 and	 IL-6	 production	 under	 basal	 conditions	 and	
following	 IL-21+CD40L	 stimulation	 were	 reduced	 in	 PPBL	 B-LCLs	 treated	 with	 3-NPA	 compared	 to	
untreated	 controls	 (Fig.	 5a).	 Targeting	 SDHA	 expression	 with	 siRNA	 in	 PPBL	 B-LCLs	 reduced	 SDHA	
protein	expression	by	40%,	complex	II	respiration	by	25%,	and	it	also	diminished	the	production	of	IL-6	
(Fig.	5b),	indicating	that	SDHA	activity	in	PPBL	B	cells	was	associated	with	increased	IL-6	production.	
Monomethyl	fumarate	(a	cell-permeable	form	of	fumarate)	also	enhanced	IL-6	production	by	1.6-fold	in	
treated	cells	compared	to	untreated	controls	 (Supplementary	Fig.	4a).	Monomethyl	 fumarate	is	more	
electrophilic	than	fumarate,	thus	introducing	the	potential	for	unwanted	reactivity.	To	induce	a	buildup	
of	endogenous	fumarate,	we	depleted	fumarate	hydratase	(FH)	in	HC	MZ-like	B-LCLs	using	siRNA,	which	
resulted	in	increased	abundance	of	intracellular	fumarate	and	production	of	IL-6	compared	to	si-control	
treated	cells	(Fig.	5c),	indicating	excess	fumarate	was	sufficient	to	boost	IL-6	production.	Modulation	of	
pyruvate	import,	or	inhibition	of	glutaminolysis,	did	not	have	a	major	impact	on	IL-6	production	in	PPBL	
B-LCLs	(Supplementary	Fig.	4b),	pointing	to	the	metabolic	flexibility	of	these	cells	in	fueling	SDH	activity.	
Next,	 we	 performed	 whole	 exome	 sequencing	 (WES)	 of	 primary	 PPBL	 B	 cells	 from	 blood.	 Initial	
interrogation	of	WES	data	did	not	identify	known	genetic	abnormalities	previously	linked	to	PIDs	(data	
not	shown).	Focusing	on	rare	genetic	variants	in	genes	encoding	mitochondrial	proteins	revealed	rare	
variants	(G135G,	A45T,	A449V)	with	high	Combined	Annotation	Dependent	Depletion	(CADD)	scores	in	
the	SDHA	gene	from	all	three	PPBL	patients	(Supplementary	Table	2).	To	independently	confirm	these	
genetic	 findings,	 an	 additional	patient	with	 clinical	 PPBL	 (patient	15;	 Supplementary	Table	 1a)	was	
recruited	into	the	study.	Total	B	cells	from	patient	15	also	displayed	elevated	OCR	but	not	ECAR	compared	
to	total	B	cells	from	HC	(Supplementary	Fig.	4c).	WES	identified	an	L649E	frame	shift	variant	in	the	SDHA	
gene	of	patient	15	(Supplementary	Table	2).	Next,	we	introduced	the	A45T	mutation	from	patient	8	into	
one	allele	of	SDHA	in	HC	MZ-like	B-LCLs	using	CRISPR/Cas9	technology.	Expression	of	the	SDHA-A45T	
mutant	increased	complex	II-specific	OCR	and	IL-6	production	compared	to	(what)	cells	transfected	with	
control	 oligonucleotides	 (Fig.	 5d),	 suggesting	 that	 gain-of-function	mutations	 in	 SDHA	 promoted	 an	
inflammatory	response.	
SDHA	catalyzes	oxidation	of	succinate	to	fumarate	and	transfers	the	resulting	electrons	to	SDHB	via	the	
electron	transporting	coenzyme	flavin	adenine	dinucleotide	(FAD).	Because	the	Ala45	residue	is	located	
at	the	highly	 flexible	N-terminal	segment	of	SDHA,	which	 interacts	with	SDHB,	 the	highly	hydrophilic	
side-chain	 of	 Thr	 in	 the	 A45T	 variant	 could	 form	 hydrogen	 bonds	 with	 SDHB,	 which	 stabilizes	 the	
complex	and	favors	complex	II	respiration.	Using	molecular	dynamics	(MD)	simulation,	H-bonds	between	
the	N-terminal	segment	of	SDHA	and	residues	Asp20-Pro21-Asp22	of	SDHB	formed	randomly	and	at	the	
same	 rate	 in	 both	 wild-type	 SDHA	 (WT-SDHA)	 and	 SDHA-A45T	 (Supplementary	 Fig.	 4d	 and	
Supplementary	 Video	 1).	 However,	 while	 interactions	 between	 SDHA	 and	 SDHB	 lasted	 2-3	 ns	 and	
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involved	mostly	one	atom	pair	in	WT-SDHA,	these	interactions	lasted	10-12	ns	and	involved	2-3	atom-
pairs	in	SDHA-A45T	(Fig.	5e,	Supplementary	Fig.	4d	and	Supplementary	Video	V1),	indicating	a	stronger	
hydrogen	bond	 interaction	between	SDHA-A45T	and	SDHB.	Asp20	and	Asp22	of	SDHB	accounted	 for	
more	than	90%	of	the	hydrogen	bonds	with	Ala43,	Ser44	and	Lys46	of	SDHA,	whilst	hydrogen	bonds	with	
either	Ala45	or	the	mutant	variant	Thr45	were	similarly	negligible	(Supplementary	Fig.	4e).	However,	
Thr45	 in	 SDHA-A45T	 formed	 stronger	 intra-molecular	 interactions	 with	 Arg458,	 Phe459,	 Asp511,	
Arg512	and	Met514	residues	on	SDHA	compared	to	Ala45	in	WT-SDHA	(Supplementary	Fig.	4f).	These	
new	intra-molecular	interactions	maintained	the	SDHA	N-terminal	segment	in	a	particular	conformation	
that	 favored	 interaction	 with	 SDHB.	 Aligning	 with	 the	 MD	 data,	 compound	 SDHA-SDHB	 activity,	
measured	spectrophotometrically,	was	higher	in	B-LCLs	from	patient	8	as	compared	to	HC	MZ-like	B-
LCLs	(Supplementary	Fig.	4g).	These	results	suggested	that	increased	interaction	between	SDHA-A45T	
and	SDHB	may	drive	the	increased	function	of	mutant	SDH.	
	
Fumarate	drives	Nrf2-dependent	transcription	of	IL-6	
In	 human	 monocytes,	 fumarate	 accumulation	 during	 initial	 stimulation	 augments	 the	 production	 of	
inflammatory	 cytokines	 upon	 re-activation	 by	 inhibiting	 histone	 demethylation	 (known	 as	 ‘trained	
immunity’)21.	Transcriptomic	analysis	of	total	PPBL	B	cells	and	'fumarate-trained'	monocytes21	indicated	
the	gene	expression	profiles	of	these	cell	types	did	not	correlate	(Supplementary	Fig.	5a).	Additionally,	
no	difference	in	pan-histone	3	(H3)	methylation	was	detected	in	total	B	cells	from	PPBL	patients	and	HC	
(Supplementary	Fig.	5b),	 ruling	out	 global	 effects	on	histone	methylation.	 Succination	of	proteins	by	
fumarate	 can	 alter	 function29,	 30.	 Using	 an	 antibody	 that	 recognized	 the	 stable	 adduct	 formed	 by	
succination,	i.e.	S-2-(succino)cysteine	(2SC),	for	immunoblot	analysis	indicated	that	protein	succination	
was	more	pronounced	in	primary	PPBL	B	cells	compared	to	HC	total	B	cells,	with	the	most	prominent	
band	appearing	at	 a	 size	between	60-70	kD	 (Fig.	6a).	 Succination	of	 reactive	 cysteines	on	KEAP1	by	
fumarate	 has	 been	 described	 in	 cancer	 cells	 with	 loss-of-function	 mutations	 in	 FH	 and	 consequent	
accumulation	of	fumarate31.	Re-probing	stripped	2SC	immunoblots	with	a	monoclonal	antibody	against	
KEAP1	 revealed	 a	 band	 at	 the	 same	 position	 as	 the	 prominent	 2SC	 band	 in	 PPBL	 B	 cells	 (Fig.	 6a).	
Succination	was	detected	on	KEAP1	immunoprecipitated	from	PPBL	B-LCLs,	but	not	on	KEAP1	from	HC	
MZ-like	B-LCLs	(Fig.	6b).	
Constitutive	 binding	 of	 KEAP1	 to	 the	 transcription	 factor	 Nrf2	 targets	 Nrf2	 for	 ubiquitin-dependent	
degradation32,	33.	KEAP1	succination	destabilizes	KEAP1-Nrf2	interaction,	allowing	nuclear	translocation	
of	 Nrf2	 and	 the	 transcription	 of	 target	 genes31,	 34	 and	 p62-mediated	 targeting	 of	 KEAP1	 for	
autophagosomal	degradation35.	Using	 imaging	flow	cytometry,	KEAP1	was	 found	to	be	homogenously	
and	 diffusedly	 distributed	 in	 HC	 total	 B	 cells,	 whereas	 KEAP1	 was	 sequestered	 to	 an	 undefined	
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cytoplasmic	 compartment	 in	primary	PPBL	B	 cells	 (Fig.	6c).	K67	 is	 a	KEAP1	activator	 that	prevents	
KEAP1	degradation	by	blocking	KEAP1	and	phosphorylated-p62	interaction.	Immunoblots	indicated	that	
the	phosphorylation	status	of	p62	was	similar	between	PPBL	B-LCLs	and	HC	MZ-like	B-LCLs	under	basal	
conditions	as	well	as	after	 IL-21+CD40L	activation	(Fig.	6d),	 indicating	 that	K67	was	able	 to	prevent	
KEAP1	degradation	in	both	B-LCL	populations.	K67	treatment	of	PPBL	B-LCLs	reduced	IL-6	production	
compared	to	untreated	controls	(Fig.	6d).	Additionally,	primary	PPBL	B	cells	treated	with	K67	had	lower	
Nrf2	 nuclear	 accumulation	 compared	 to	 untreated	 HC	 (Supplementary	 Fig.	 5c),	 demonstrating	 that	
stabilizing	KEAP1	with	K67	restricted	Nrf2	activity.	Of	note,	Nrf2	was	more	abundant	in	nuclei	extracted	
from	PPBL	B-LCLs	compared	to	HC	MZ-like	B-LCLs	(Fig.	6e).	Using	GSEA,	canonical	targets	of	Nrf2,	such	
as	GCLC	and	NQO1,	were	not	enriched	in	PPBL	B	cells	compared	to	MZ-like	B	cells	from	HC	(data	not	
shown).	However,	quantification	of	transcripts	by	qPCR	indicated	a	slightly	higher	abundance	of	GCLC,	
GLCM,	NQO1	and	TXNRD1	 in	PPBL	B-LCLs	compared	to	HC	MZ-like	B-LCLs	(Supplementary	Fig.	5d).	
Metabolomics	 analyses	also	 identified	 increased	abundance	of	 glutathione	 (reduced	GSH	and	oxidize	
GSSG)	in	primary	PPBL	B	cells	compared	to	MZ-like	B	cells	from	HC	(Supplementary	Fig.	5d).	Further,	
the	GSH/GSSG	ratio	in	PPBL	B	cells	was	greater	than	in	HC	MZ-like	B	cells	(data	not	shown),	indicating	a	
reductive	state	in	PPBL	B	cells	that	is	typically	associated	with	constitutively	active	Nrf236.	
Treatment	with	the	Nrf2	inhibitor	ML-385	reduced	IL-6	production	in	non-activated	and	IL-21+CD40L-
activated	 PPBL	 B-LCLs	 compared	 to	 untreated	 controls	 (Fig.	 6f).	 ML-385	 also	 largely	 abrogated	
monomethyl	 fumarate-driven	production	of	 IL-6	in	MZ-like	B-LCLs	from	HC	(Supplementary	Fig.	5e).	
Inversely,	addition	of	the	Nrf2	activator	CDDO	enhanced	NQO1	and	IL6	transcript	abundance	in	PPBL	and	
HC	 MZ-like	 B-LCLs	 under	 basal	 and	 IL-21+CD40L	 activating	 conditions	 (Supplementary	 Fig.	 5f).	
Depletion	of	Nrf2	protein	using	siRNA	interference	robustly	decreased	the	production	of	IL-6	mRNA	and	
protein,	 in	 PPBL	 B-LCLs	 from	 all	 three	 patients	 compared	 to	 si-control	 transfected	 cells	 (Fig.	 6g).	
Computational	 approaches	 identified	 Nrf2	 binding	 motifs	 in	 the	 promoters	 of	 IL6,	 IL1B	 and	 CXCL8	
(Supplementary	 Table	 3).	 ChIP-PCR	 indicated	 increased	 binding	 of	 Nrf2	 binding	 in	 both	 predicted	
binding	sites	 in	 the	 IL6	promoter	as	well	as	 to	 the	promoter	of	 the	canonical	Nrf2	targets	NQO1	and	
HMOX1	in	primary	PPBL	B	cells	compared	to	total	B	cells	from	HC	(Fig.	6h).	Lastly,	inhibition	of	Nrf2	with	
ML385	in	primary	human	B	cells	stimulated	with	CpG	for	24	h	blunted	IL-6	production	in	IgD+CD27-	naïve	
B	 cells,	 and	 only	 had	a	moderate	 effect	 in	 CD27+	memory	 B	 cells	 (Supplementary	Fig.	 5g),	whereas	
treatment	with	ML385	had	no	appreciable	effect	on	the	surface	expression	of	CD69,	CD86,	HLADR	and	
CD71	in	both	subsets	(Supplementary	Fig.	5g).	Activation	of	KEAP1	with	K67	did	not	impact	production	
of	 IL-6	 in	 both	 B	 cell	 subsets	 (Supplementary	 Fig.	 5g).	 Together,	 these	 data	 indicated	 that	 excess	
production	of	IL-6	in	PPBL	B	cells	was	mediated	by	triggering	the	KEAP1–Nrf2	axis.		
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To	test	whether	blocking	IL-6	may	have	clinical	efficacy,	we	treated	patient	8	with	a	single	dose	of	the	IL-
6	 receptor-blocking	 antibody,	 tocilizumab.	 	 Four	 weeks	 after	 tocilizumab	 treatment,	 there	 was	 no	
detectable	 effect	 on	 antibody	amounts,	T	 and	B	 cell	 numbers	 and	B	 cell	 subset	distribution	 in	blood	
compared	to	pre-treatment	blood	samples	(Supplementary	Table	4),	however,	a	slight	reduction	in	CRP	
and	BSR	was	observed	(Fig.	6i,	Supplementary	Fig.	5h),	suggesting	reduced	systemic	inflammation.	In	
addition,	a	clinical	questionnaire	 taken	before	and	two	weeks	 into	tocilizumab	treatment	suggested	a	
beneficial	impact	of	blocking	IL-6	signaling	in	this	patient	with	regard	to	symptoms	of	malaise	and	night	
sweats	(Fig.	6i,	Supplementary	Fig.	5h).	Together,	mutations	in	SDHA	drove	accumulation	of	fumarate,	
which	 in	 turn	 led	 to	 inhibition	of	KEAP1,	 likely	 through	 succination,	 and	 the	 consequent	Nrf2-driven	
inflammatory	reprogramming	of	PPBL	B	cells	(Supplementary	Fig.	5i).	 	
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DISCUSSION	
In	a	prospective	screening	approach,	we	found	that	mitochondrial	respiration	was	higher	in	B	cells	from	
patients	with	PAD.	In	a	subset	of	patients	with	the	most	pronounced	phenotype,	hyper-respiration	was	
determined	to	be	due	to	gain-of-function	variants	in	SDH,	which	were	identified	as	the	cause	of	fumarate	
accumulation,	protein	succination	and	inflammatory	reprogramming	of	B	cells	in	3	PPBL	patients.	This	
inflammatory	B	cell	reprogramming	aligned	with	the	clinical	phenotype	observed	in	these	patients.	In	
one	 PPBL	 patient,	 enhanced	 activity	 of	 SDH	 and	 accumulation	 of	 fumarate	 was	 traced	 to	 a	 gain-of-
function	mutation	in	SDHA	(SDHAA45T),	and	resulted	in	the	increased	production	of	IL-6.	
Nrf2	activation	following	oxidative	or	electrophilic	stress	typically	promotes	an	anti-inflammatory	state	
by	 reducing	 intracellular	 ROS	 and	 by	 inhibiting	 the	 expression	 of	 pro-inflammatory	 cytokines	 and	
chemokines37.	However,	Nrf2	also	supports	inflammation	by	stabilizing	the	activation	of	NLRP3	and	AIM2	
inflammasomes,	 and	 by	 promoting	 inflammation	 in	 dextran	 sulfate	 sodium	 (DSS)	 colitis	models	 and	
inducing	IL-8	expression	in	kidney	mesangial	cells38,	39.	These	disparate	roles	in	modulating	inflammation	
suggest	that	Nrf2	function	is	context	dependent,	as	evidenced	by	the	protective	and	tumor	promoting	
roles	of	Nrf2	in	cancer40.	In	PPBL	B	cells,	SDH-dependent	accumulation	of	fumarate	and	succination	of	
KEAP1	resulted	in	constitutive	activation	of	Nrf2	that	drove	IL-6	expression.	This	agrees	with	reports	
that	 IL-6	 transcription	 was	 mediated	 by	 Nrf2	 in	 hepatocytes41.	 Systemic,	 low-grade	 inflammation	
observed	 in	PPBL	 is	potentially	due	 to	chronic	elevated	 IL-6.	 Indeed,	blockade	of	 IL-6	signaling	using	
tocilizumab	in	one	PPBL	patient	alleviated	inflammation	and	improved	quality	of	life.		
In	PPBL,	the	majority	of	circulating	B	cells	typically	have	an	IgD+CD27+	MZ-like	phenotype.	MZ-like	B	cells	
produce	 inflammatory	 cytokines,	 reflecting	 their	 function	 as	 innate-like	 sensors	 of	 the	 immune	
response27.	 The	 genetic	 basis	 for	 this	 differentiation	 bias	 towards	 MZ-like	 B	 cells	 in	 PPBL	 remains	
unknown.	Normal	MZ-like	B	cell	differentiation	is	dependent	on	Notch	signaling	in	humans	and	mice42,	43,	
44,	45.	Notch1	expression	in	hepatocytes	is	partially	mediated	by	Nrf246.	Increased	basal	Nrf2	activity	could	
thus	potentially	enhance	Notch	signaling	in	transitional	B	cells	and	drive	differentiation	towards	MZ-like	
B	 cells.	 Smoking	 is	 highly	 associated	with	progression	 to	PPBL.	 Increased	amounts	of	 fumarate	were	
reported	in	the	serum	of	smokers47.	Cigarette	smoke	can	also	enhance	the	expression	of	OxPhos	proteins,	
including	SDHA,	 in	 lung	cells48	and	drive	Nrf2	activation49.	 It	can	be	speculated	 that	activation	of	 the	
fumarate–KEAP1–Nrf2	axis	 in	cigarette	smoking	PPBL	patients	reflects	an	extreme	variant	of	a	much	
more	common,	smoking-associated	immunometabolic	dysregulation.	
All	 four	 patients	 with	 PPBL	 carried	 different	 rare	 germline	mutations	 in	 SDHA.	 We	 provided	 direct	
experimental	 evidence	 and	 detailed	 structural	 modeling	 to	 establish	 the	 effects	 of	 SDH-A45T	 (from	
patient	8)	on	SDHA	function.	In	silico,	Thr45	in	SDHA-A45T	stabilized	the	interactions	between	SDHA	and	
SDHB.	How	the	mutations	in	SDHA	in	patient	9	and	patient	15	induced	gain-of-function	at	the	molecular	
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level	 remains	 to	 be	 determined.	 The	mutation	 in	 patient	 1	 is	 synonymous.	 Synonymous	 rare	 codon	
variants	 play	 important	 functional	 roles	 in	 the	 regulation	 of	 co-translational	 folding	 and	 covalent	
modifications	in	vivo50,	the	mutation	identified	here	might	be	subject	to	a	similar	mechanism.		
	
In	summary,	this	study	identified	SDHA	gain-of-function	as	a	disease	modifier	in	PPBL,	driving	fumarate	
accumulation,	succination	and	inflammatory	reprogramming	of	B	cells.	Representing	the	first	example	of	
a	 primary	mitochondrial	 retrograde	 signaling	 pathology,	 our	 data	 point	 to	 therapeutic	 repurposing-
strategies	 by	 uncovering	 druggable	 targets,	 namely	 SDHA,	 Nrf2	 and	 IL-6	 along	 this	 dysregulated	
molecular	axis.	 	
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FIGURE LEGENDS (for main text only) 
Figure 1. Metabolic B cell profile of HC and patients with primary antibody deficiency. 
(a) OCR (left) and ECAR (right) of CD19+ B cells from HC (n = 15) and patients with primary antibody 
deficiency (PAD) (n = 14). (b) C-reactive protein (CRP) measurement over time (black line) and clinical 
symptoms (arrows) from patient 9 (upper). One measurement per time point. Histopathology of a skin biopsy, 
showing perivascular neutrophilic infiltration and nuclear debris (black arrowheads) and deposition of fibrin 
(red arrowheads) (lower left). Scale bar, 100 µm. Abdominal MRI scan showing a contrast enhanced soft-tissue 
dense area (red arrow) around the aorta, reflecting periaortitis (lower right). (c) Representative flow cytometry 
dot plots from a HC and a PPBL patient showing subset distribution of CD19+ B cells stained with IgD and 
CD27 antibodies. Experiments were performed with 3 independent donors (d) Baseline OCR and ECAR 
measurements (T0) of primary total B cells and MZ-like B cells from HCs (each n = 4) and primary B cells 
from PPBL patients (n = 3) following mitochondrial perturbation with oligomycin (Oli), FCCP, and rotenone 
(Rot). Representative OCR/ECAR profiles of 6 independent experiments (left), and summary bar graphs of 
basal OCR/ECAR (right). Follow-up measurements of OCR and ECAR one year after baseline assessment (= 
T12) of primary B cells from HCs (n = 4) and primary B cells from PPBL patients (n = 3) (lower). Representative 
OCR/ECAR profiles of 3 independent experiments (lower left), and summary bar graphs of basal OCR/ECAR 
(lower right). (e) Mitochondrial perturbation profiles of primary B cells from a HC, and from PPPBL Patient 9 
before (upper) and during sirolimus (2 mg/d) treatment of the patient (lower). OCR of each individual was 
measured once per time point and performed in triplicate. (f) ECAR measurements of primary B cells from HCs 
(n = 3) and PPBL patients (n = 3) before and following injection of IL-21+CD40L directly into the metabolic 
flux analyzer (dashed line). ECAR profile is representative of 3 independent experiments (left), summary bar 
graphs of glycolytic switch indicating area under the curve (AUC) post-activation (right). (g) Flow cytometry 
histogram, reflecting glucose (2-NBDG) uptake of primary B cells from HCs (n = 3) and PPBL patients (n = 3) 
activated with IL-21 plus CD40L for 24 hours prior to analysis. Shown data are representative of 3 independent 
experiments (left), respectively, are summarized in bar diagram (right). 
Data are represented as mean ± SEM. Statistical significance was assessed by one-way ANOVA (a), or two-
sided unpaired t-test (d-g). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, ns, not significant. See also 
Figure S1. 
 
Figure 2: Activity of individual mitochondrial respiratory chain complexes in PPBL B cells. 
(a) Activity-assays for CI, CII, CIV, and CV, depicted as changes in absorbance over time, comparing B-LCLs 
derived from HC (n = 3) and PPBL (n = 3) B cells. Graphs are representative of 4 independent experiments 
(left), and summarized in bar graphs (right). (b) OCR measurements of permeabilized B-LCLs from HCs (n = 
4) and PPBL patients (n = 3) prior to and following addition of complex specific substrates as indicated (dashed 
lines). Data are shown as OCR graphs (left) representative of 4 independent experiments, and summary bar 
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graphs of complex specific OCRs (right). (c) OCR measurements of permeabilized B-LCLs of HCs (n = 3) and 
PPBL patients (n = 3), prior to and following addition of succinate, ADP and rotenone or inhibitors, as indicated 
(dashed lines). OCR graphs are representative of 2 independent experiments (left), and summarized as bar 
graphs (right). (d) Representative immune blot analysis (left) and quantification (right) of isolated mitochondria 
from B-LCLs of HCs (n = 4) and PPBL patients (n = 3) probed for Grim19, SDHA, and Tom20. 
Pooled data are represented as mean ± SEM. Statistical significance was assessed by two-sided unpaired t-test 
(a-d). * p < 0.05, ** p < 0.01, ns, not significant. See also Figure S2. 
 
Figure 3: Metabolic characterization of PPBL B cells. 
(a) Fold change in glycolysis and TCA cycle metabolites between primary B cells from PPBL patients (n = 3) 
and primary MZ-like B cells from HCs (4 samples pooled of n = 7 donors). Significantly different metabolites 
are shown in color, with the fold change color-coded from light to dark blue (left). Bar graphs of relative 
abundance of glycolysis and TCA cycle metabolites (right). (b) Abundance of succinate and fumarate in EBV 
immortalized cells derived from MZ-like B cells from HCs (n = 3) and B cells from PPBL patients (n = 3). (c) 
Ratio of the abundance of α-ketoglutarate (α-KG) over (succinate + fumarate), and fumarate over succinate, 
both in primary MZ-like B cells from HCs and primary B cells from PPBL patients (donors as in (a)). (d) 
Metabolic tracing analysis of primary B cells from PPBL patients (n = 3) incubated for 6 hours with 13C-glucose 
or 13C-glutamine. Bar graphs show distribution of mass isotopologues, the scheme depicts the primary labeling 
of glucose- and glutamine-derived 13C fueling into the TCA cycle.  
Pooled data are shown as mean ± SEM. Statistical significance was assessed by two-sided Welch's two-sample 
t-test, minima, maxima (box) mean (horizontal line) (a), two-sided unpaired t-test (b,c). * p < 0.05, *** p < 
0.001, ns, not significant.	
 
Legend to Figure 4: Transcriptional profile of PPBL B cells. 
(a) Hierarchical clustering (heatmap) of sample correlation (left), and MA plot of transcriptome data (right) 
from primary MZ-like B cells of HCs (n = 4) and primary B cells from PPBL patients (n = 3). (b) mRNA 
abundance of MZ-like B cell marker (donors as in (a)). (c) Heatmap of relative expression of genes encoding 
complex II (donors as in (a)). (d) Gene set enrichment analysis of inflammatory-response genes (left) and IL-6-
Jak-Stat3 pathway genes (right) (donors as in (a)). ES = enrichment score. (e) Heatmap of relative expression 
of mRNA encoding for IL-8, IL-1b, CCL5, IL-6 and TNF (donors as in (a)). (f) Production of IL-6 and IL-8 
protein by MZ-like B-LCLs from HCs (n = 3) and B-LCLs from PPBL patients (n = 3) untreated or treated for 
48 hours with IL-21+CD40L. Data are pooled from 3 independent experiments. (g) Quantification of IL-6 
protein in the serum of PPBL patient 8. Measurements were performed on two separate occasions. Dashed line 
= reference value (< 3.1 ng/l)  
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Pooled data are shown as minima, maxima (box), mean (horizontal line) (b) and mean ± SEM (f). Statistical 
significance was assessed by two-sided unpaired t-test (f). * p < 0.05, ** p < 0.01. See also Figure S3. 
 
Legend to Figure 5: SDHA activity and inflammatory cytokine production. 
(a) Representative mitochondrial perturbation profile of B-LCLs from a PPBL patient untreated or incubated 
with the SDHA inhibitor 3-nitropropionic acid (3-NPA) for 12 hours prior to the experiment. The bar graph 
summarizes basal mitochondrial respiration of B-LCLs from PPBL patients (n = 3) (left). Representative 
mitochondrial respiration profile of permeabilized B-LCLs from a PPBL patient prior to and following addition 
of complex II specific substrates (succinate, ADP, malonate) as indicated (dashed lines). B-LCLs were untreated 
or exposed to 3-NPA for 12 hours prior to the assay. The bar graph summarizes changes in complex II OCR of 
B-LCLs from PPBL patients (n = 3) (middle). Quantification of IL-6 production by B-LCLs from PPBL patients 
(n = 3). Cells were non-activated or activated with IL-21 plus CD40L, in the presence or absence of 3-NPA for 
48 hours. Data are representative of 3 independent experiments. (right). (b) Immunoblot analysis of B-LCLs 
from PPBL patients transfected with control siRNA, or SDHA siRNA, and probed for SDHA protein abundance. 
The bar graph summarizes knockdown efficiency in B-LCL from PPBL patients (n = 3) of 3 independent 
experiments (left). Representative data and quantification of mitochondrial respiration profile of permeabilized 
B-LCLs from PPBL patients (n = 3) prior to and following addition of complex II specific substrates as indicated 
(dashed lines). B-LCLs were treated with either control siRNA or SDHA siRNA prior to the assay (middle). IL-
6 was quantified in the supernatant of B-LCLs from PPBL patients (n = 3), transfected with control siRNA or 
SDHA siRNA, and cultured for 48 hours. Each patient cell line was tested 3 times (right). (c) Immunoblot 
analysis of marginal zone-like B-LCLs from HCs (n = 3) transfected with control siRNA, or fumarate hydratase 
(FH) siRNA, and probed for FH protein abundance. Shown data are representative of 3 independent experiments 
(left), respectively, are summarized in bar diagram (middle). IL-6 was quantified in the supernatant of both cell 
populations after 48 hours of cell culture (right). (d) Representative data (left) and quantification (middle) of 
complex II specific respiration of SDHA WT and SDHA (A45T) in marginal zone-like B-LCLs from HC. IL-6 
was quantified in the supernatant of both cell populations after 48 hours of cell culture (right). Data are 
representative for 3 independent experiments. (e) Time per interaction between SDHA and SDHB, calculated 
as area under the curve (AUC), of each individual simulation replica (n=12) (WT vs. A45T). (f) Molecular 
representation of the 'SDHA (green) SDHB (blue)' complex, shown in ribbons. The prosthetic group flavin 
adenine dinucleotide (FAD) is shown as sticks and CPK colored (black arrowhead). Residues of the N-ter of 
SDHA within 2.5 Å of SDHB are shown as sticks and CPK colored.  
Pooled data are shown as mean ± SEM. Statistical significance was assessed by two-sided paired t-test (a, b), 
and one-way ANOVA (e). * p < 0.05, ** p < 0.01, *** p < 0.001. See also Figure S4. 
 
Legend to Figure 6: Fumarate accumulation, KEAP1–Nrf2 activity and IL-6 production. 
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(a) Representative immunoblot analyses probing primary B cells of HC and PPBL patients for S-(2-
succino)cysteine (2SC), followed by stripping and re-staining for KEAP1. The bar graph represents 
quantification of 2SC abundance in primary B cells of HCs (n = 3) and PPBL patients (n = 3). (b) Representative 
immunoblots of endogenous KEAP1 immunoprecipitated from Patient 1 and HC B-LCLs. Blots were probed 
with KEAP1 or 2SC antibodies (n = 1). (c) Representative imaging flow cytometry images of primary bulk B 
cells from a HC and a PPBL patient. Cells were stained for KEAP1 (red) and a nuclear marker (DAPI, purple). 
Histograms depict similarity dilate scores of KEAP1 nuclear localization in all cells analyzed (n = 1) (d) 
Phosphorylation of p62 was assessed by immunoblotting both in non-activated and activated PPBL (n = 3) and 
HC MZ-like (n = 3) B-LCLs. Summary bar graphs and representative blot is shown (left). Production of IL-6 
by B-LCLs from PPBL patients (n = 3) treated with K67 or with DMSO in the presence or absence of IL-
21+CD40L for 48 hours (right). Each patient cell line was independently tested 3 times. (e) Representative 
immunoblots (left) and quantification (right) of Nrf2 nuclear abundance from B-LCLs derived from HC MZ-
like B cells (n = 3) or PPBL B cells (n= 3). (f) Quantification of IL-6 production by B-LCLs from PPBL patients 
(n = 3). Cells were non-activated or activated with IL-21 plus CD40L, in the presence or absence of the Nrf2 
inhibitor, ML-385 or with vehicle (DMSO) for 48 hours. Data are pooled from 3 independent experiments. (g) 
Representative immunoblot analysis of Nrf2 protein abundance in B-LCLs of a PPBL patient transfected with 
control or NRF2 si-RNA (lower left). The bar graph summarizes knockdown efficiency of B-LCLs from PPBL 
patients (n = 3) (upper left). IL-6 mRNA and protein (supernatant) was quantified in both cell populations after 
48 hours of culture (right). Each patient cell line was independently tested 3 times. (h) Binding of Nrf2 to the 
IL-6 gene promoter (two predicted binding sites: Tbl. S3) (left), and the NQO1 and HMOX1 gene promoters 
(right) in primary PPBL B cells (n = 3) and HC marginal zone-like B cells (n = 2). (i) CRP and BSR 
measurements before and after IL-6 receptor blockade (left).  Result of the patient questionnaire filled by the 
patient (right).  
Pooled data are shown as mean ± SEM. Statistical significance was assessed by two-sided unpaired t-test (a,e,h 
(right panel)), Wilcoxon signed rank test (f), two-sided paired t-test (d,g), and two-way ANOVA (h, left panel). 
* p < 0.05, ** p < 0.01, ns, not significant. See also Figure S5.  
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METHODS	
Study	subjects	
The	 study	 was	 approved	 by	 the	 Ethikkommission	 Nordwest-	 und	 Zentralschweiz	 (EKNZ	 2015-187);	
complied	with	all	relevant	ethical	regulations,	and	informed	consent	was	obtained	from	all	participants.	
Fourteen	patients,	and	15	age	and	sex	matched	HC,	were	prospectively	recruited	between	July	2015	and	
December	2016.	One	additional	PPBL	patient	was	recruited	2018.	Inclusion	criteria	for	patients	were	as	
follows:	Age	>18	years;	serum	IgG	level	<7g/l,	or	IgG	subclass	deficiency	(IgG1	<4.9	g/l,	IgG2	<1.5	g/l,	IgG3	
<0.2	g/l,	IgG4	<0.08	g/l).	Patients	evaluated	by	a	Clinical	Immunologist	and	classified	as	having	a	form	of	
secondary	antibody	deficiency	were	excluded	from	the	study.	
	
Blood	sample	routine	phenotyping	and	immunoglobulin	quantification	
After	written	informed	consent,	blood	samples	 from	patients	and	HC	(Blood	donor	Center,	University	
Hospital	Basel)	were	obtained.	 From	all	 patients	a	differential	white	blood	 cell	 count,	 including	 total	
lymphocyte	as	well	as	T	and	B	cell	absolute	numbers,	were	obtained.	B	cells	(CD19+	in	lymphocyte	gate)	
were	 further	 phenotyped	 as	 follows:	 naïve	 B	 cells	 (IgD+CD27–IgM+),	 marginal	 zone-like	 B	 cells	
(IgD+CD27+IgM+),	memory	B	 cells	 (IgD–CD27+IgM–),	 transitional	B	 cells	 (IgD+IgM+CD38+),	 CD21	 low	B	
cells	 (CD21lowCD38–),	 and	 plasmablasts	 (IgD–IgM–CD38++).	 T	 cells	 (CD3+	 in	 lymphocyte	 gate)	 were	
classified	into:	CD4+	T	cells,	CD8+	T	cells,	naïve	(CD27+CD45RO–)	vs.	central	memory	(CD27+CD45RO+)	vs.	
effector	memory	(CD27–CD45RO+/–).	Serum	levels	of	total	IgG	and	IgG	subclasses	(IgG1-4);	IgM;	IgA	(data	
not	shown),	and	IgE	(data	not	shown)	were	quantified.	All	above	experiments	were	performed	at	the	
accredited	Medical	Immunology	Laboratory	(ISO	17025)	of	the	University	Hospital	Basel.	
	
Cell	sorting	and	phenotyping	
Peripheral	blood	mononuclear	cells	(PBMCs)	were	isolated	by	standard	density-gradient	centrifugation	
(Lymphoprep	Fresenus	Kabi,	Norway).	B	cells	(CD19+)	and	T	cells	(CD3+)	were	positively	selected	using	
magnetic	beads	(Miltenyi	Biotec,	Germany)	according	to	the	manufacturer’s	instructions.	For	isolation	of	
marginal	 zone-like	 B	 cells,	 B	 cells	 (CD19+)	 were	 stained	 with	 anti-CD27	 brilliant	 Violet	 605	 (O323)	
(Biolegend,	USA)	and	anti-IgD	VioBlue	(REA740,	Miltenyi	Biotec)	mAb.	CD19+	CD27+	IgD+	B	cells	were	
sorted	with	a	BD	Influx	cell	sorter	(BD	Bioscience,	USA).	FACS	sorted	naïve	and	memory	B	cells	(as	above)	
were	activated	with	CpG	(2.5	µg/ml)	for	24	hours	and	then	stained	with	anti-CD86-PE	(IT2.2,	Biolegend),	
anti-CD69-FITC	 (FN50,	 Immunotools),	 anti-HLADR-APC	 (G46-6,	 BD	 Biosciences),	 and	 anti-CD71-PE	
(CY1G4,	 Biolegend).	 For	 carboxyfluorescein	 succinimidyl	 ester	 (CFSE)	 dilution	 assays,	 PBMCs	 were	
stained	with	CFSE	and	then	activated	with	anti-CD3	and	anti-CD28	mAb	(for	T	cells),	or	with	CpG	or	IL-
21/CD40L	(for	B	cells).	Cells	were	stimulated	for	5	days	and	then	assessed	by	flow	cytometry.	For	CMV	
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ELISPOT	 assays	 patient	 and	 HC	 PBMCs	 were	 stimulated	 CMV	 antigens	 using	 the	 T-track	 CMV	 kit	
(Lophius).	 For	 detailed	 B	 cell	 phenotyping	 the	 following	 additional	 antibodies	were	 used:	 anti-CD24	
(IML5,	Biolegend),	anti-CD38	(HIT2,	BD	Biosciences),	anti-TACI	(1A1,	Biolegend).	
	
EBV	transformed	B	lymphocyte	cell	lines	
PBMCs	or	sorted	marginal	zone-like	B	cells	were	incubated	with	EBV-containing	supernatant	from	B95-
8	cells	for	1	hour	and	additionally	stimulated	with	CpG	(1	μg/ml).	Cyclosporine	A	(1	μg/ml)	was	added	
weekly	for	a	total	of	four	weeks	to	eliminate	T	cells.	Purity	of	EBV	transformed	B	cell	lines,	as	defined	by	
flow	cytometry,	was	92-98	%	(CD19+	CD3–).	
	
Metabolic	flux	analysis	
A	Seahorse	XF-96e	extracellular	flux	analyzer	(Seahorse	Bioscience,	Agilent	Technologies,	USA)	was	used	
to	define	oxygen	consumption	rates	(OCR)	and	extracellular	acidification	rates	(ECAR).	Mitochondrial	
perturbation	experiments	were	carried	out	by	sequential	addition	of	oligomycin	(1	μM,	Sigma-Aldrich,	
USA),	 FCCP	 (2	 μM,	 Carbonyl	 cyanide	 4-(trifluoromethoxy)	 phenylhydrazone,	 Sigma-Aldrich),	 and	
rotenone	 (1	μM,	 Sigma-Aldrich).	 For	measuring	activation-induced	glycolytic	 activity,	primary	B	 cells	
were	activated	with	IL-21	(200	ng/ml,	ImmunoTools,	Germany)	and	CD40L	(200	ng/ml,	Sigma-Aldrich)	
injected	into	the	metabolic	flux	analyzer	via	injection	ports,	and	ECAR	was	monitored	in	real	time.	For	
monitoring	OCR	of	intact	mitochondria	only,	cells	were	resuspended	in	MAS	buffer	(70	mM	sucrose,	220	
mM	mannitol,	10	mM	KH2PO4,	5	mM	MgCl2,	2	mM	HEPES,	and	1	mM	EGTA),	then	treated	with	the	XF	
plasma	membrane	permeabilizer	(Seahorse,	Agilent	Technologies),	which	was	followed	by	addition	of	
pyruvate	(5	mM)	/	malate	(2.5	mM)	/	ADP	(1	mM)	and	rotenone	(1	μM)	for	monitoring	complex	I-driven	
respiration;	succinate	(10	mM)	/	ADP	(1	mM)	with/without	rotenone	(1	μm	/	2	μm)	and	malonate	(0.04	
mM)	for	monitoring	complex	II-driven	respiration;	duroquinol	(0.5	mM)	/	ADP	(1	mM)	and	antimycin	A	
(0.02	mM)	for	monitoring	complex	III-driven	respiration;	TMPD	(0.5	mM)	/	Ascorbate	2	mM)	/	ADP	(1	
mM)	and	sodium	azide	(20	mM)	(all	from	Sigma-Aldrich)	for	monitoring	complex	IV-driven	respiration.	
Changes	in	OCR	upon	substrate	addition	were	calculated	relative	to	the	pre-injection	rate.	
	
2-NBDG	uptake	
To	assess	glucose-uptake,	5x105	primary	B	cells	were	activated	with	IL-21	(200	ng/ml,	ImmunoTools)	
and	CD40L	(200	ng/ml,	Sigma-Aldrich)	for	24	hours.	Cells	were	then	incubated	in	medium	containing	20	
μM	2-NBDG	(Invitrogen)	for	45	min	and	analyzed	by	flow	cytometry.	
	
Electron	microscopy	
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Transmission	electron	microscopy	was	performed	at	the	Biozentrum	(University	of	Basel).	Primary	B	
cells	were	sequentially	fixed	in	3%	paraformaldehyde,	0.5%	glutaraldehyde	and	1%	osmium	tetraoxide,	
embedded	and	then	cut	into	60	nm	sections.	Micrographs	(27’000x	magnification)	were	obtained	with	a	
Morgagni	268	 (FEI,	 Hillsboro	OR,	 USA)	 transmission	 electron	microscope	 operated	 at	 80	 kV.	 ImageJ	
software	(NIH,	Bethesda,	USA)	was	used	for	measuring	cell	area;	mitochondrial	area,	and	mitochondrial	
length	(major	axis)	and	width	(minor	axis).	The	aspect	ratio	of	mitochondria	was	calculated	as	 ‘major	
axis’	over	‘minor	axis’,	an	aspect	ratio	of	1	indicating	a	circular	mitochondrial	section.	
	
Isolation	of	mitochondria	
Cell	pellets	were	washed	with	cold	PBS	and	lysed	using	RIPA	buffer	(Thermo	Fisher	Scientific,	Rockford	
IL,	USA)	containing	protease	and	phosphatase	inhibitors	(Roche,	Switzerland).	To	prepare	mitochondrial	
fractions,	3x107	B-LCLs	were	collected	and	washed	with	buffer	A	(83	mM	sucrose,	10	mM	MOPS,	pH	7.4).	
Cell	pellets	were	then	homogenized	with	20	strokes	in	a	tightly	fitting	glass-teflon	homogenizer	with	1	
ml	of	buffer	B	(buffer	A	plus	10mM	triethanolamine,	5%	percoll,	0.01%	digitonin,	protease	inhibitor,	pH	
7.4).	Nuclei	and	unbroken	cells	were	removed	by	centrifugation	at	2’500	x	g	for	5	min.	Supernatants	were	
collected	and	centrifuged	at	10’000	x	g	for	15	min.	Mitochondria	were	then	suspended	in	an	appropriate	
volume	of	buffer	C	(300	mM	sucrose,	EGTA	1	mM,	20mM	MOPS,	protease	inhibitor,	pH	7.4)	for	storage	at	
−80°C	until	use.	
	
Immunoblot	analysis	
Whole-cell	lysates	or	mitochondrial	fractions	were	separated	by	4-15%	Mini	Protean	TGX	Gel	(Bio-Rad,	
Hercules	CA,	USA),	and	transferred	to	nitrocellulose	using	Trans-Blot	Turbo	Transfer	(Bio-Rad,	Hercules	
CA,	USA).	Membranes	were	probed	with	anti-Grim19	mAb	(ab110240),	anit-NDFU8	mAb	(ab110242),	
anti-SDHB	mAb	(ab14714),	anti-Complex	III	subunit	Core	2	mAb	(ab14745),	anti-Complex	IV	subunit	II	
mAb	 (ab110258),	 anti-ATPα	 mAb	 (ab14748),	 anti-ATP5A	 mAb	 (ab176569),	 Anti-UQCRC2	 mAb	
(ab14745),	 anti-MTCO2	mAb	 (ab110258)	 and	 anti-Tomm20	mAb(ab56783)(all	 from	 Abcam),	
anti-SDHA	mAb	(119989),	anti-FH	mAb	(4567),	anti-KEAP1	mAb	(8047),	anti-Nrf2	pAb	(12721),	pan-
methyl-histone	H3	(Lys9)	mAb	(4473)	and	anti-β-actin	mAb	(3700)	(all	from	Cell	Signaling,	USA)	and	
anti-2SC	pAb	(crb2005017e,	Cambridge	Research	Biochemicals,	UK).	Blots	were	then	stained	with	the	
appropriate	secondary	antibody	(IRDye	800CW-conjugated	goat	polyclonal	antibody	against	rabbit	IgG	
(926-32211)	or	RDye	800CW-conjugated	goat	polyclonal	antibody	against	mouse	IgG	(926-32219)	from	
LI-COR).	The	Odyssey	imaging	system	(LICOR)	was	used	for	detection,	and	the	ImageJ	software	(1.48v)	
for	quantification.	
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Blue	native	PAGE	
For	isolation	of	mitoplasts,	8	x	106	B-LCLs	were	re-suspended	in	100	μl	of	PBS,	32.5	μl	of	digitonin	(8	
mg/ml)	was	added	and	cells	were	incubated	on	ice	for	10	min.	Cold	PBS	(1	ml)	was	added	and	cells	
were	centrifuged	for	5	min	at	10’000	x	g.	The	pellet	was	resuspended	in	100	μl	of	AA	buffer	(500	mM	
6-aminohexanoic	acid,	50	mM	immidazole,	1	mM	EDTA,	pH	7)	and	10	μl	of	a	10%	digitonin	solution	
was	added.	Next,	cells	were	centrifuged	for	30	min	at	18’000	x	g.	Supernatant	was	harvested	and	10	
μl	of	sample	buffer	(5%	blue	G-250,	5%	glycerol	in	AA	Buffer)	was	added.	BN-PAGE	was	performed	as	
described51.	Membranes	were	probed	for	anti-NDUFA9	mAb	(20C11B11B11,	Abcam),	anti-complex	II	
70	kDA	Fp	mAb	 (459200,	 Invitrogen),	Anti-UQCRC1	mAB	(16D10AD9AH5)	(110252,	Abcam),	anti-
oxphos	Complex	IV	Subunit	 I	mAb	(459600,	Invitrogen),	anti-ATPB	antibody	[3D5]	 -	Mitochondrial	
Marker	mAb	(14730,	Abcam)	and	Tomm20	(FL-145)	(sc11415,	Santa	Cruz	Biotechnology,	USA).	
	
Mitotracker	red	and	mitotracker	deep	red	staining	
Primary	 B	 cells	 were	 incubated	 for	 20	 min	 at	 37°C	 /	 5%	 CO2	 with	 100	 nM	Mitotracker	 red	 (MTR,	
Invitrogen),	or	100	nM	Mitotracker	deep	red	(MTDR,	Invitrogen),	respectively.	Cells	were	then	washed	
twice	in	staining	buffer	(PBS	plus	1%	bovine	serum	albumin)	and	analyzed	by	flow	cytometry.	
	
Activity	of	individual	respiratory	chain	complexes	
To	measure	the	activity	of	individual	mitochondrial	respiratory	chain	complexes,	ELISA	microplate	assay	
kits	(Abcam,	UK)	were	used	according	to	the	manufacturer’s	instructions.	
	
Metabolomics	
Cells	 from	 primary	 patient	 B	 cells	 and	 primary	marginal	 zone-like	 B	 cells	 from	HC	were	 isolated	 as	
described	above,	washed	twice	with	cold	PBS,	snap	frozen	in	EtOH	containing	dry	ice	and	stored	at	−80°C.	
Metabolomic	assays	and	analysis	were	performed	by	Metabolon	 Inc.	 (Durham,	USA).	 Importantly,	the	
settings	used	enabled	the	separation	of	methylmalonate	from	the	isobaric	succinate.	The	two	metabolites	
succinate	and	fumarate	were	analyzed	by	electrospray	ionization	in	the	negative	mode	using	multiple	
reaction	 monitoring.	 Metabolomics	 data	 can	 be	 accessed	 under:	
www.ebi.ac.uk/metabolights/MTBLS1137	
	
13C6	glucose	and	13C6	glutamine	tracing	
Primary	B	cells	(2x106)	from	patients	were	plated	onto	48	well	plates	in	RPMI10-FBS	with	4	mM	U-13C	
glucose	 or	 4	mM	U-13C	 glutamine	 for	 6	 hours.	Metabolites	were	 extracted	with	 50	%	MeOH	 /	 30	%	
Acetonitrile.	 Isotopologue	distribution	was	assessed	by	GC-MS.	Metabolites	were	extracted	 from	cells	
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using	ice-cold	80	%	methanol,	followed	by	sonication	and	removal	of	cellular	debris	by	centrifugation	at	
4°C.	Metabolite	extracts	were	dried,	derivatized	as	tert-butyldimethylsilyl	(TBDMS)	esters,	and	analyzed	
via	GC-MS.	Uniformly	deuterated	myristic	acid	 (750	ng	 /	 sample)	was	 added	as	an	 internal	standard	
following	cellular	metabolite	extraction,	and	metabolite	abundance	was	expressed	relative	to	the	internal	
standard,	and	normalized	to	cell	number.	Mass	isotopomer	distribution	was	determined	using	a	custom	
algorithm	developed	at	McGill	University,	Canada52.	
	
RNA	sequencing	
RNA	from	primary	patient	B	cells	and	primary	marginal	zone-like	B	cells	 from	HC	was	 isolated	using	
nucleospin	 RNA	 kit	 (Macherey-Nagel,	 Germany)	 following	manufacturer’s	 instructions.	 RNA-seq	was	
performed	by	Admera	Health	(USA).	Obtained	single-end	RNA-seq	reads	were	mapped	to	 the	human	
genome	assembly,	version	hg38	(analysis	set,	downloaded	from	UCSC	https://genome.ucsc.edu),	with	
RNA-STAR,	with	 default	 parameters	 except	 for	 reporting	 for	multi-mappers	 only	 one	 hit	 in	 the	 final	
alignment	 files	 (outSAMmultNmax=1)	 and	 filtering	 reads	 without	 evidence	 in	 spliced	 junction	 table	
(outFilterType="BySJout").").	 All	 subsequent	 gene	 expression	 data	 analysis	 was	 done	 within	 the	 R	
software	(R	Foundation	for	Statistical	Computing,	Vienna,	Austria).	Raw	reads	and	mapping	quality	was	
assessed	by	the	qQCreport	function	from	the	R/Bioconductor	software	package	QuasR	(version	1.18.0).	
Using	Ensembl	Genes	mRNA	coordinates	from	ensembl	version	88	(https://www.ensembl.org)	and	the	
qCount	function	from	QuasR	package,	we	quantified	gene	expression	as	the	number	of	reads	that	started	
within	any	annotated	exon	of	a	gene.	Only	genes	with	valid	Entrez	Gene	Id	were	kept.	The	differentially	
expressed	 genes	 were	 identified	 using	 the	 edgeR	 package	 (version	 3.20.9)53.	 RNA	 seq	 data	 can	 be	
accessed	under	the	GEO	accession	number	(GSE135173).	
	
Whole	exome	sequencing	
The	Oragene	DNA	OG-500	kit	(DNA	Genotek	Inc.,	Canada)	was	used	to	collect	saliva	from	patients,	DNA	
was	extracted	using	PrepIT	L2P	reagent	(DNA	Genotek	Inc.).	Sonication	as	well	as	library	preparation	
was	performed	using	the	SureSelectXT	Target	Enrichment	System	for	Illumina	Paired-End	Sequencing	
Library	 Protocol	 (Version	 C0,	 December	 2016).	 SureSelectXT	 Reagent	 kits	 were	 used	 for	 library	
preparation	(Agilent	Technologies).	Exon-specific	biotinylated	oligonucleotides,	SureSelect	Human	All	
Exon	 V6	 (Agilent	 Technologies),	 were	 hybridized	 with	 the	 samples.	 Exons	 were	 pulled	 down	 using	
Dynabeads	 MyOne	 Streptavidin	 T1	 magnetic	 beads	 (Thermo	 Fisher	 Scientific).	 Paired-end	 125	 bp	
sequencing	was	performed	on	HiSeq	4000	Illumina	platform.	Output	files	from	the	sequencer	were	in	
FASTQ	format.	Paired-end	sequencing	resulted	in	two	FASTQ	files	for	each	sample,	forward	and	reverse.	
Forward	and	reverse	FASTQ	files	were	aligned	to	the	reference	genome	(hg19)	using	Burrows-Wheeler	
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Aligner.	The	output	of	BWA	was	a	sequence	alignment	map	(SAM)	file.	Picard	tools	v2.7.1	was	used	to	
make	a	binary	version	of	SAM	files	(=BAM	files).	Quality	control	was	performed	as	per	Genome	Analysis	
Tool	Kit	(GATK)	v3.5	guidelines	from	Broad	Institute54.	Each	output	BAM	file	was	individually	analyzed	
for	variants	from	the	reference	genome	using	HaplotypeCaller	from	GATK	resulting	in	a	variant	called	file	
(VCF).	Annotation	of	mutations	was	performed	using	Combined	Annotation	Dependent	Depletion	(CADD	
v1.3)	and	Variant	effect	predictor	(VEP)	programs.	Mutations	of	interest	were	visualized	in	silico	using	
the	 Integrative	Genomics	Viewer	 (IGV)	 in	order	 to	 confirm	 the	mutation	was	 in	 fact	 somatic	and	not	
present	in	controls.	The	synonymous	mutation	was	further	investigated	for	splice	altering,	miRNA	site,	
or	mRNA	structure	altering,	using	NNSplice,	Human	Splicing	Finder,	TargetScan		and	Rescue	ESE55,	56.	
Somatic	analysis	was	performed	using	VarScan	v2.3.9	(ref	57),	Strelka	Somatic	Caller	and	MuTect2	(refs.	
58,	 59).	 Annotation	 of	 somatic	mutations	 from	 the	 3	 callers	was	performed	 using	 CADD	 v1.3	 and	 VEP	
programs.	 The	 WES	 data	 can	 be	 accessed	 under	 the	 BioProject	 number	 PRJNA557194	
(https://www.ncbi.nlm.nih.gov/sra/PRJNA557194).	
	
Cytokine	measurements	
B-LCLs	(4	x	106)	from	patients,	and	marginal	zone-like	B-LCLs	from	HC,	were	plated	into	48	well	plates.	
Cells	 were	 either	 left	 unstimulated	 (non-activated	 controls),	 or	 activated	 with	 IL-21	 (40	 ng/ml,	
ImmunoTools)	and	CD40L	(40	ng/ml,	Sigma-Aldrich).	As	indicated,	3-NPA	(1.5	μM,	Sigma-Aldrich),	ML-
385	(5	μM,	Sigma-Aldrich),	SML-1922	(50	μM,	Sigma-Aldrich)	or	monomethyl	 fumarate	(25	μM)	was	
added.	Supernatants	were	harvested	48	hours	after	activation,	and	concentrations	of	IL-6	was	measured	
using	Legendplex,	human	multiplex	Panel	(Biolegend),	according	to	the	manufacturer’s	instructions.	
	
RNA	mediated	interference	
B-LCLs	(2x106)	from	patients,	and	marginal	zone-like	B-LCLs	from	HC,	were	transfected	with	pools	of	
siRNA	targeting	SDHA,	NRF2,	or	control	scrambled	siRNA	(each	30	pmol)	(QIAGEN)	and	rested	for	48	
hours,	 using	 the	AMAXA	cell	 line	V	nucleofection	kit	 (Lonza).	Knockdown	efficiency	was	assessed	by	
immunoblot	analyses	of	the	respective	proteins.	
	
CRISPR-editing	
Introduction	 of	 the	 SDHA	A45T	 point	mutation	 into	 B-LCLs	 from	HC	marginal	 zone-like	 B	 cells	was	
performed	by	Genoway.	
	
Molecular	dynamics	simulation	
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Interaction	between	SDHA	and	SDHB	were	studied	using	MD	simulations.	To	date	no	structures	of	human	
SDHA	or	SDHB	have	been	published,	yet	the	crystal	structure	of	porcine	heart	mitochondrial	complex	II	
has	been	solved	at	3.1	Å	resolution	(PDB	code	4YTP)60.	To	generate	a	model	of	the	human	SDHA/SDHB	
complex,	 the	 sequence	 of	 the	 protein,	 as	 obtained	 from	 the	 US	 National	 Centre	 for	 Biotechnology	
Information	 (https://www.ncbi.nlm.nih.gov	 -	 accessed	 22nd	 February	 2018),	 was	 submitted	 to	 the	
automated	protein	structure	homology-modeling	server,	SWISS-MODEL61.	Using	the	VMD62	and	Chimera	
suites63,	a	complex	of	human	SDHA	and	SDHB	was	designed.	Two	different	models	were	generated,	each	
extended	at	 the	N-ter	with	 segments	of	 sequence	ASAKVSDSI	(wt)	and	ASTKVSDSI	(A45T	mutation),	
respectively62,	64.	The	structure	of	FAD	was	obtained	 from	the	Zinc	library	and	their	parameters	were	
calculated	 through	 the	 CHARMM	 General	 Force	 Field	 (CGenFF)	 version	 1.0.065.	 Simulations	 were	
conducted	 with	 the	 GROMACS	 package,	 version	 2016.366,	 using	 parallel	 tempering.	 The	 CHARMM36	
topology	and	parameter	files	were	used	to	represent	the	protein	and	water	was	represented	by	the	TIP3P	
model,	whereas	parameters	 for	FAD	were	 calculated	with	CGenFF65.	 Isotropic	pressure	 at	 1	bar	was	
virtually	maintained	through	coupling	to	a	Parrinello-Rahman	barostat67,	with	a	virtual	compressibility	
of	4.5	x	10–5	bar	and	a	coupling	time	of	5	ps.	For	parallel	tempering,	an	ensemble	of	48	temperatures	in	
the	range	310-385K	was	generated,	whereas	solute	and	solvent	were	weakly	coupled	to	Nose-Hoover68	
thermostats	with	coupling	times	of	1	ps69.	Each	individual	trajectory	was	~22.5-23.0	ns	long,	totalizing	
1100	 and	 1080	 ns	 for	 the	wt	 and	 the	 A45T	mutant,	 respectively.	 The	 trajectories	 simulated	 for	 at	 a	
temperature	 lower	 than	 360K	 were	 retained	 for	 the	 analyses,	 which	 were	 conducted	 either	 on	 the	
statistical	platform	R	and	specific	R	packages,	GROMACS	tools,	or	in-house	Python	scripts70.	
	
SDHA	end	point	PCR	and	sequencing	
RNA	 was	 isolated	 from	 B-LCL	 (5	 x	 106)	 of	 patient	 #8	 using	 Trizol	 (Thermo	 Fisher	 Scientific)	 and	
chloroform	(Sigma-Aldrich)	according	 to	 the	manufacturer’s	protocol,	 then	purified	with	 the	QIAamp	
RNA	Blood	Mini	Kit	(QIAGEN,	Germany).	Random	primers	(Promega,	USA)	were	annealed	at	70°C	for	5	
min.	cDNA	synthesis	was	performed	according	to	the	Qiagen’s	GoScript	Reverse	Transcription	System	
protocol	in	a	TProfessional	TRIO	PCR	Thermocycler	(Core	Life	Sciences,	USA).	To	search	for	the	mutation	
in	the	cDNA	of	patient	#8,	primers	were	designed	to	amplify	a	fragment	of	the	SDHA	transcripts	by	using	
the	 ncbi	 primer	 blast	 web	 tool	 (https://www.ncbi.nlm.nih.gov/tools/primer-blast/).	 The	 following	
primers	were	used:	Forward	primer:	CGA	CTC	CGG	CGT	GGT	G;	Reverse	primer:	TTT	TCT	AGC	TCG	ACC	
ACG	 GC.	 End	 point	 PCR	was	 performed	 using	 cDNA	 of	 B-LCL	 from	 patient	 #8,	 and	 Go	 Taq	 G2	 DNA	
Polymerase	 (Promega)	 with	 the	 GoTaq	 Green	 Master	 Mix	 (Promega)	 in	 a	 TProfessional	 TRIO	 PCR	
Thermocycler	 (Core	 Life	 Sciences).	 PCR	 products	 were	 separated	using	 a	 1.5%	 agarose	 gel	
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electrophoresis	and	the	band	around	the	expected	 length	of	534	bp	was	extracted	and	purified	using	
Qiaquick	Gel	Extraction	Kit	(QIAGEN).	Extracted	DNA	was	used	for	Sanger	sequencing.	
	
SDHA	plus	SDHB	activity	
SDH	activity	(i.e.	compound	activity	of	SDHA	and	SDHB)	was	measured	spectrophotometrically	from	the	
reduction	of	2,6-diclorophenol-indophenol	(DCPIP)	by	tracking	the	absorbance	at	600	nm	over	3	min.	
Specifically,	 frozen	 B-LCLs	 (5	 x	 106)	 were	 thawed	 and	 resuspended	 in	 100	 μl	 PBS	 on	 ice,	 protein	
concentration	 was	 determined,	 and	 the	 volume	 was	 adjusted	 to	 the	 sample	 with	 the	 lowest	
concentration.	 Each	 sample	 (20	 μl)	 was	 suspended	 in	 950	 μl	 of	 buffer	 C1/C2	 (25	 mM	 potassium	
phosphate	(K2HPO4)	(pH	=	7.2),	5	mM	MgCl2,	3	mM	KCN,	2.5	mg/ml	BSA)	supplemented	with	100	mM	
succinate	and	0.1%	Triton	X-100,	and	incubated	10	min	at	room	temperature.	After	addition	of	6	μl	5	mM	
DCPIP,	2	μl	1	mg/ml	of	antimycin	A	and	2	μl	1	mM	rotenone,	samples	were	incubated	for	2	min.	Then,	6	
μl	of	10	mM	phenazine	methosulfate	(PMS)	was	added	and	absorbance	was	measured.	Compound	activity	
of	SDHA	and	SDHB	was	extrapolated	using	the	following	formula:	[SDH	activity	=	((rate/min)/19.1)	/	
sample	volume	x	1000	x	dilution	factor],	where	19.1	is	the	molar	extinction	coefficient	at	30°C	(mM−1	
cm−1).	
	
Overexpression	
B-LCLs	were	nucleofected	(Lonza)	with	Flag-KEAP1	for	24	or	48	hours.	Flag-KEAP1	was	a	gift	from	Qing	
Zhong	(UC	Berkeley).	KEAP1	interacting	proteins	were	purified	using	anti-FLAG	antibodies	(clone	9A3,	
Cell	 signaling)	 and	 identified	 by	 affinity	 purification	 MS.	 Transfection	 efficiency	 was	 assessed	 by	
Immunoblots.	
	
Imaging	Flow	cytometry	
Primary	B	cells	from	HC	and	PPBL	patients	were	fixed	with	4%	paraformaldehyde	and	permeabilized	
with	0.3%	Triton-X	100.	Cells	were	blocked	with	5%	goat	 serum	and	stained	with	primary	antibody	
(Keap1-mAb	Ms,	Thermo-Fisher;	Nrf2-pAb	Rb,	Abcam)	in	blocking	medium	at	4°C,	overnight.	Cells	were	
then	stained	with	secondary	antibodies	(Thermo	Fisher)	and	counterstained	with	DAPI.	 Images	were	
acquired	using	the	Imagestream	X	Mark	II	imaging	flow	cytometer	(AMNIS).	Between	1000-2000	events	
were	collected	and	imaged	at	60x	magnification.	For	analysis,	the	nuclear	localization	wizard	from	the	
IDEAS	 software	 (AMNIS)	 was	 used.	 High	 similarity	 dilate	 mean	 scores	 reflect	 increased	 nuclear	
localization.	For	assessment	of	Nrf2	nuclear	translocation	following	addition	of	Keap1	activation,	cells	
were	treated	with	K67	for	24	hours	and	then	fixed	for	staining	as	above.	
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ChIP-PCR	
ChIP-PCR	was	performed	by	Active	Motif.	In	brief,	human	B	cells	were	fixed	with	1%	formaldehyde	for	
15	min	 and	 quenched	with	 0.125	M	 glycine.	 Chromatin	was	 isolated	 by	 the	 addition	 of	 lysis	 buffer,	
followed	by	disruption	with	a	Dounce	homogenizer.	Lysates	were	sonicated	using	the	EpiShear™	Probe	
Sonicator	 (Active	Motif)	with	 an	 EpiShear™	 Cooled	 Sonication	 Platform	 (Active	Motif)	 and	 the	 DNA	
sheared	to	an	average	length	of	300-500	bp.	Genomic	DNA	(Input)	was	prepared	by	treating	aliquots	of	
chromatin	with	RNase,	proteinase	K	and	heat	for	de-crosslinking	(overnight	at	65°C)	followed	by	ethanol	
precipitation.	 Pellets	 were	 resuspended	 and	 the	 resulting	 DNA	 was	 quantified	 on	 a	 CLARIOStar®	
spectrophotometer.	 Extrapolation	 to	 the	original	 chromatin	 volume	allowed	quantitation	of	 the	 total	
chromatin	 yield.	 Aliquots	 of	 chromatin	 (25	 µg)	 were	 precleared	 with	 protein	 A	 agarose	 beads	
(Invitrogen).	Genomic	DNA	regions	of	interest	were	isolated	using	an	antibody	against	NRF2	(Santa	Cruz	
Biotechnologies,	cat.	no.	sc-13032),	Complexes	were	washed,	eluted	from	the	beads	with	SDS	buffer,	and	
subjected	to	RNase	and	proteinase	K	treatment).	Crosslinks	were	reversed	by	incubation	overnight	at	
65°C,	 and	 ChIP	 DNA	 was	 purified	 by	 phenol-chloroform	 extraction	 and	 ethanol	 precipitation.	
Quantitative	PCR	(QPCR)	reactions	were	carried	out	in	triplicate	using	SYBR	Green	Supermix	(Bio-Rad)	
on	a	CFX	Connect™	Real	Time	PCR	system.	The	resulting	signals	were	normalized	for	primer	efficiency	
by	carrying	out	QPCR	for	each	primer	pair	using	pooled	input	DNA	from	the	samples.	
	
Please	also	see	accompanying	Life	Sciences	Reporting	Summary.	 	
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DATA	AVAILABILITY	STATEMENT	
Web	 links	 for	 publicly	 available	 datasets	 are	 provided	 at	 the	 appropriate	 places	 in	 the	 manuscript,	
accession	codes	for	metabolomics,	RNAseq	and	WES	data	have	been	added	to	the	respective	methods	
sections.	No	restrictions	on	data	availability	apply.	Patient	material	may	not	be	available	anymore.	All	
figure	panels,	with	exception	of	Figure	S5G,	are	associated	with	raw	data.	 	
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Supplementary Figure 1 
Oxygen consumption rates are increased in PPBL B cells 
(a) Age distribution of basal OCR and basal ECAR in primary B cells from HCs (n = 15) and PAD patients (n = 14). (b) Basal OCR in 
primary B cells from female vs. male and CMV– vs. CMV+ HCs (n = 13) and PAD patients (n = 14). (c) Representative cell surface 
phenotype of B cells (CD19+ lymphocytes) from HCs and PPBL patients stained with CD24, CD38, TACI, and CD27 antibodies. HCs 
(n=2) and PPBL patients (n=2) were independently tested once. (d) CFSE dilution histogram of sorted CD19+ IgD+CD27–; IgD+CD27+ 
and PPBL B cells stimulated with IL-21 and CD40L or CPG for 5 days (upper panel) and summarized in bar diagram (lower graph). 
Representative of 3 independent experiments. (e) Gating strategy for sorting MZ-like B cells from healthy controls. CD19+ cells were 
discriminated based on SSC/FSC area (upper left) and doublets were gated out (upper right). MZ-like B cells are IgD+CD27+ cells 
(lower left). Sorted MZ-like B cells after FACS sorting (lower right). (f) Relative distribution of CD4+ and CD8+ T cell subsets from HCs 
(n=3) and a PPBL patients (n=3). Representative of 3 independent experiments. (g) Representative histograms of CFSE dilution 
assays of anti-CD3/anti-CD28 activated CD4+ and CD8+ T cells from a HC and a PPBL patient. Representative of 3 independent 
experiments. (h) T cell reactivity against CMV peptides (pp65 and IE-1) between HCs (n=2) and PPBL patient T cells (n=2) were 
assessed by IFN-gamma ELISpot. The result is positive if the geometric mean is > 10 (red line) (i) Representative mitochondrial 
perturbation profiles of primary T cells from HCs and PPBL patients. Summary graphs present basal OCR (left) and ECAR (middle) of 
primary T cells from HCs (n = 14) and PPBL patients (n = 3). Representative mitotracker red (MTR) and mitotracker deep red (MTDR) 
staining of primary B cells from HCs (n = 3) and PPBL patients (n = 3) (right). Representative of 3 independent experiments. 
Pooled data are presented as mean ± SEM. Statistical significance was assessed by two-sided unpaired t-test (b,h). * p < 0.05, ** p < 
0.01, ns, not significant. 
 
 
 
 
 
Supplementary Figure 2 
Complex II is hyper-functional in PPBL B cells 
(a) Representative transmission electron microscopy images of a primary B cell from a HC and a PPBL patient (left). White scale bar, 
2000 nm. Black scale bar, 1000 nm. Summary graphs of cell area; mitochondrial area; mitochondria count per cell, and mitochondrial 
aspect ratio (length/width) from HCs (n = 3) and PPBL patients (n = 3) (right). 45 B cells were analyzed per individual in 3 independent 
experiments. (b) Representative immunoblot analysis of primary B cells from a HC and a PPBL patient. Blots were probed for Complex 
I (CI) subunit NDUFB8, Complex II (CII) subunit SDHB, Complex III (CIII) subunit Core 2, Complex IV (CIV) subunit I, Complex V (CV) 
ATP synthase subunit alpha, as well as actin (upper). Bar graph depicts quantification of the abundance of each complex subunit 
relative to actin (lower). Experiment was performed once. (c) BN-PAGE immunoblot analysis of enriched mitochondria from B-LCLs of 
HCs (n = 3) and PPBL patients (n= 3), probed for CI (NDUFA9), CII (SDHA), CIII (UQCRC1), CIV (subunit I) and Tom20 (left). 
Summary bar graph (right). Representative of 4 independent experiments. (d) Representative mitotracker deep red (MTDR) and 
mitotracker red (MTR) staining of primary B cells from HCs (n = 3) and PPBL patients (n = 3). Bar graph summarizes the geometric 
mean fluorescence intensity (gMFI) of MTDR and MTR of both populations. 
Pooled data are represented as mean ± SEM. Statistical significance was assessed by two-sided Mann-Whitney test (a), two-sided 
unpaired t-test (c,d). * p < 0.05, ** p < 0.01, ns, not significant. 
 
 
 
 
 
Supplementary Figure 3 
PPBL B cells have an inflammatory transcriptional profile 
(a) Heatmap visualization of relative transcript abundance of genes involved in TCA, glycolysis and glutamine metabolism, in primary 
MZ-like B cells from HCs (n = 4) and primary B cells form PPBL patients (n = 3). (b) Heatmap visualization or relative transcript 
abundance of genes involved in respiratory complexes I, III, IV and V in primary MZ-like B cells from HCs (n = 4) and primary B cells 
form PPBL patients (n = 3). 
 
 
 
 
 
Supplementary Figure 4 
SDH drives an inflammatory phenotype in PPBL B cells 
(a) Production of IL-6 by MZ-like B-LCLs from HCs (n = 3), quantified in cell culture supernatants of cells activated for 48 hours with IL-
21 plus CD40L, in presence or absence of monomethyl fumarate. (b) Production of IL-6 by Patients B-LCLs (n = 3), quantified in cell 
culture supernatants of cells cultured for 24 hours in presence or absence of UK-5099 (1, 10 μM), BPTES (1, 10 μM) or dichloroacetate 
(DCA; 0.1, 0.5 mM). (c) OCR and ECAR measurements of primary B cells from healthy controls (n=16) and primary B cells from Patient 
#15 (PPBL patient). Basal values are shown. (d) Number of hydrogen bonds formed over time between SDHB and residues 43-46 of 
SDHA, wild type (wt vs. A45T). Red segments highlight the trajectory extract shown in Video V1. Corresponding frequency distributions 
of the counted hydrogen bonds are shown in the insets. Experiment was repeated independently 12 times with similar results (e) 
Frequency distributions of the residues from the N-terminal SDHA (left) and SDHB (right) involved in inter-domain hydrogen bonds in 
simulations with SDHA wt and SDHA A45T. (f) Time fraction of simulated contacts between Ala/Thr45 and adjacent SDHA residues 
(Arg458, Phe459, Asp511, Arg512 and Met514), depicted as a percentage of the SDHA-SDHB interaction time in wt and A45T. 
Experiment was repeated independently 12 times with similar results. (g) Visualization of Sanger sequencing of B-LCL derived cDNA of 
Patient 8, carrying the A45T mutation (left). Asterisk indicates changes of nucleotide G to A at position 133. Compound SDHA plus 
SDHB activity (enzyme complex derived from B-LCLs) from Patient 8 relative to HCs (n = 3) (right). Compound SDHA-SDHB activity 
was independently tested 4 times in Patient 8 and in the control subject. 
Pooled data are represented as mean ± SEM. Statistical significance assessed by two-sided paired t-test (a), two-sided unpaired t-test 
(g), one-way ANOVA, adjustments were made for multiple comparisons with BH procedure (f). * p < 0.05, ** p < 0.01, ns, not 
significant. 
 
 
 
 
 
Supplementary Figure 5 
Fumarate drives Nrf2-dependent transcription of IL-6 
(a) Comparison of genes that were differentially expressed between non-treated and fumarate-treated monocytes (y-axis) and those 
differentially expressed between primary MZ-like B cells from HCs (n = 4) and primary B cells from PPBL patients (n = 3) (x-axis). (b) 
Representative immunoblot probing for histone H3 methylation among primary B cells of a HC vs. PPBL patient. The bar graph 
summarizes data from HCs (n = 3) and PPBL patients (n = 3). (c) Representative imaging flow cytometry data showing nuclear 
abundance of Nrf2 in primary PPBL B cells in presence/absence of the Nrf2 inhibitor, K67. Black scale bar, 7 μm. Histograms depict 
similarity dilate scores of NRF2 nuclear localization in presence of absence of K67. Experiment was performed once. (d) mRNA 
abundance of canonical NRF2 regulated genes in PPBL B cell lines (n = 3) and cell lines derived from marginal zone-like B cells from 
HCs (n=3) (left). Abundance of GSH and GSSG from primary B cells (right) (e) Quantification of IL-6 production by MZ-like B-LCLs from 
HCs (n = 3) of cells incubated with monomethyl fumarate for 48 hours in presence vs. absence of the Nrf2 inhibitor, ML385. (f) mRNA 
abundance of NQO1 and IL6 from PPBL (n=3) and healthy MZ (n=3) B-LCLs activated with IL-21 plus CD40L in the presence or 
absence of the NRF2 activator, CDDO (1 μM). (g) Effect of Nrf2 inhibition using K67 on IL-6 production, and expression of activation 
markers, in primary naïve and memory B cells from healthy donors activated with CpG (2.5 μg/ml) for 24 hours (n = 5 healthy donors). 
(h) Schematic summary of the clinical trial performed in Patient 8. (i) Graphical summary of the model proposed from this study. 
Pooled data are shown as mean ± SEM. Correlation in (a) was assessed using Pearson’s r, statistical significance was assessed by 
two-sided unpaired t-test (b,e,d [right]), two way ANOVA (d [left]). 
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Table S1 
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Pt  Sex Age  (at dx) Infection Lymphoproliferation Autoimmunity Others 
♯1 f 46 herpes simplex, sinusitis, bronchitis hepatomegaly raynaud syndrome 
athralgia, 
spontanious, rib 
fractures 
♯2 f 45 bronchitis, pneumonia splenomegaly   athralgia 
♯3 m 21 sinusitis, bronchitis pneumonia 
splenomegaly, 
retroperitoneal 
lymphadenopathy  
vitiligo   
♯4 f 62 postinterventional wound infections       
♯5 m 58   splenomegaly, axilar lymphadenopathy 
autoimmune 
thrombocytopenia   
♯6 m 30   splenomegaly 
autoimmune hemolytic 
anaemia/ 
thrombocytopenia 
aphthous ulcers 
♯7 m 25 akne inversa, skin abscesses mild splenomegaly     
♯8 f 51 
otitis, sinusitis, 
bronchitis, candida 
oesophagitis 
mild splenomegaly    fatigue, weight loss 
♯9 m 54 bronchitis mild splenomegaly perichondritis, scleritis, tendinis, vascultis   
♯10 f 41 bronchitis, sinusitis, pneumonia 
bilateral hilar 
lymphadenopathy   fatigue 
♯11 f 35 bronchits, sinusitis   diabetes mellitus    
♯12 f 59 bronchits, pyelonephritis   spondylarthritis   
♯13 f 34 sinusitis   autoimmune keratitis fatigue 
♯14 f 59 bronchitis, pneumonia,  urinary tract infections  
retroperitoneal 
lymphadenopathy 
autoimmune 
thrombocytopenia/ 
neutropenia 
  
♯15 f 42 
recurrent sinusitis, 
meningitis in 1st year 
of life 
 
Lupus like disease (ANA, 
Anti-DNS), Polyarthritis, 
mild nephropathy 
fatigue 
b 
  IgG  g/l IgM g/l Naïve /                         μl  
Marginal zone 
like   / μl  
Class switched       
/μl  
CD21low                 
/μl  
Transitional             
/μl  
Plasmablasts          
/μl  
      
 CD19+ CD27- 
IgD+ IgM+ 
 CD19+ CD27+ 
IgD+ IgM+ 
 CD19+ CD27+ 
IgD- IgM- 
CD19+ CD21low   
CD38- 
CD19+ CD38+ 
IgD+ IgM+ 
CD19+ 
CD38++ IgD- 
IgM- 
Ref 
value  1-7 0.4-2.3 66-228  8-172 8-102  1-12 1-5 1-5 
Pt              
♯1 5.9 9.04 225 2471 82 94 6 <3 
♯2 IgG4< 0.05 2.76 128 72 28 5 6 <1 
♯3 0.9 0.22 143 28 <1 6 2 <1 
♯4 5.8 2.19 87 33 16 4 4 1 
♯5 3.4 0.45 150 99 4 8 6 <1 
♯6 4.3 0.22 95 13 2 5 <1 <1 
♯7 6.7 0.36 244 33 9.1 3 5 <1 
♯8 4.4 4.47 554 2168 11 39 3 <3 
♯9 5 7.75 276 455 28 71 9 5 
♯10 2.85 0.24 332 32 5 6 11 <1 
♯11 3.5 1.15 81 86 11 1 1 <1 
♯12 3.6   289 74 16 3 10 <1 
♯13 6.3 2.21 156 92 69 2 5 <1 
♯14 1.6 1.47 170 3 <1 40 9 <1 
♯15 6.1 10 1006 367 125 112 17 <1 
	
	
	
c 
 
CD4 Naïve 
relative 
CD4 Central 
memory 
CD4 Effector 
memory CD4 TEMRA 
CD4 Follicular 
T helper 
CD4 Recent 
thymic 
emigrants 
(RTE) 
CD4 Treg CD4 activated 
Ref 
value  
15.7-54.7 % of 
CD4+ T cells 
8-28.8% of 
CD4+ T cells 
16.8-57.4% of 
CD4+ T cells 
3.6-23.2% of 
CD4+ T cells 
6.9-19.1% of 
CD4+ T cells 
14.1-37.2% of 
naïve CD4+ T 
cells 
6.1-11% of 
CD4+ T cells 
4.5-15.6% of 
CD4+ T cells 
Pt                  
♯1 33.80 26.50 33.30 6.40 18.50 21.90 11.70 5.60 
♯8 49.50 24.30 22.00 4.10 9.90 20.90 6.60 3.90 
♯9 18.70 34.50 43.60 3.10 19.00 9.00 11.20 8.80 
♯15 13.00 37.50 47.10 2.40 25.40 7.00 4.90 4.80 
         
 
CD8 naïve 
relative 
CD8 Central 
memory 
CD8 Effector 
memory CD8 TEMRA CD8 activated    
Ref 
value  
7-62.5% of 
CD8+ T cells 
0.6-4.4% of 
CD8+ T cells 
4.3-64.5% of 
CD8+ T cells 
8.1-60.5% of 
CD8+ T cells 
5.7-48.2% of 
CD8+ T cells 
   
Pt               
♯1 50.40 6.30 28.40 14.90 9.70    
♯8 43.50 4.90 28.30 23.20 9.10    
♯9 27.50 6.70 24.80 41.00 34.40    
♯15 20.50 8.80 40.80 29.90 16.80    
	
	
	
	
Table S2 
 
Pt Chr Basepair  pos. cDNA Zygosity Gene       symbol 
Amino        
acid rsID ESP 
CADD-   
PHRED 
Poly       
Phen2 
SIFT       
score 
♯1 5 225975 c.C405T HET SDHA G135G  rs61733344 0.001 20.4 NA NA 
♯8 5 223551 c.G133A HET SDHA A45T rs140736646 0 23 0.002 0.16 
♯9 5 236513 c.C1346T HET SDHA A449V rs201139276 NA 26.8 0.585 0.02 
♯15 5 256483 c.1945_1946delTT HET SDHA L649Efs rs112307877 0 33 NA NA 
 
Chr = chromosome; rsID = single nucleotide polymorphism database identifier; ESP = Grand Opportunity Exome Sequencing Project; CADD = Combined 
Annotation Dependent Depletion; PolyPhen2 = Polymorphism Phenotyping 2; SIFT = Sorting Intolerant from Tolerant; NA = Not Applicable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S3 
 
ARE sequence ARE orientation  Position of ARE  Gene Entrez Gene ID UCSC ID 
ATTACTATGCG sense -795 IL6 3569 uc064bxs.1 
GTGACTCAGCA antisense -232   uc064bxt.1 
GTGATGTAGCC antisense -2924 IL1b 3553 uc002tii.2 
GTGATCATGCA sense -2129    
TTTACATAGCA sense -1573 CXCL8 3576 uc003hhe.3 
ATGATTGTGCA sense -1358    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S4 
a                                                                   b 
 
  
Ref value Pre-Actemra 
Post-   
Actemra 
IgG 7.0-16.0 g/l 7.2 6.4 
IgG1 4.90-11.40g/l 4.39 3.7 
IgG2 1.50-6.40g/l 2.31 2.05 
IgG3 0.20-1.10g/l 0.36 0.34 
IgG4 0.08-1.40g/l 0.18 0.16 
IgA 0.70-4.00g/l 0.56 0.49 
IgM  0.40-2.30g/l 4.95 5.21 
 
 
c 
  
Ref value Pre-     Actemra 
Post-
Actemra 
Naïve B cells relative 25.1-92.4% of B cells 51.1 49.7 
Naïve B cells absolute 66-228/μl 783 976 
Marginal zone like B cells 
relative 3.1-59.7% of B cells 44.6 48.2 
Marginal zone like B cells 
absolute 8-172/μl 684 947 
Memory B cell relative 2.4-32.6% of B cells 0.7 0.9 
Memory B cell absolute 8-102/μl 11 18 
CD21lo B cells relative 0.5-4.7% of B cells 4.4 3.6 
CD21lo B cells absolute 1-12/μl 67 70 
Transitional B cells relative 0.3-2.9% of B cells 0.2 0.2 
Transitional B cells absolute 1-5/μl 3 4 
Plasmablasts relative 0.1-3% (of B cells) 0.1 0.1 
Plasmablasts absolute 1-5/μl 2 2 
 
  Ref value Pre-Actemra 
Post- 
Actemra 
T cells relative 55-86% (of lymphocytes) 49 44 
T cells absolute 742-2750/μl 1691 1725 
B cells relative 5-22% (of lymphocytes) 45 53 
B cells absolute 80-616/μl 1533 1964 
